

MARGARET D. WEISS, MD PHD FRCP(C)

Margaret D. Weiss, MD, PhD, FRCP(C), is currently the Director of Clinical Research in Child Psychiatry at Cambridge Health Alliance, Cambridge MA. She has specialized in diagnosis, treatment and research in ADHD and other neurodevelopmental disorders in all age groups. She received her MD and Fellowship in Psychiatry from McGill University and her PhD in the History of Science from Harvard University. Dr. Weiss has published over 125 peer-reviewed articles relating to these topics. Dr. Weiss is known for her research demonstrating that melatonin is a safe and effective treatment for initial insomnia in ADHD. She is the author of the Weiss Functional Impairment Rating Scale, a widely used measure translated into 18 languages. She is on the advisory council of the Canadian Attention Deficit Disorder Resource Alliance, and the board of the American Professional Association for ADHD and Related Disorders.

**The Faculty of Medicine of Harvard University
Curriculum Vitae**

Date Prepared: May 27, 2022
Name: Margaret Danielle Weiss
Office Address: 1493 Cambridge St., Cambridge MA 02139
Home Address: 38 Braeland Ave. No 1, Newton MA 02459
Work Phone: 617 665 1338
Work Email: madweiss@challiance.org
Place of Birth: Montreal, Quebec

Education:

09/1972- 05/1976	B.A.	Biology & History	Brandeis University
09/1976- 05/1978	M.A.	History of Science	Harvard University
1978-05/1985	Ph.D.	History and Philosophy of Science	Harvard University
09/1979- 06/1983	M.D.C.M.	Medical School	McGill University

Postdoctoral Training:

07/83-06/84	Straight Intern	Psychiatry	McGill University
07/85-11/88	Resident	Psychiatry	McGill University

Faculty Academic Appointments:

1988-1992	Associate Professor	Psychiatry	McGill University
1992-1998	Clinical Assistant Professor	Psychiatry	University of British Columbia
1998-2007	Clinical Associate Professor	Psychiatry	University of British Columbia

2007-2017	Clinical Professor	Psychiatry	University of British Columbia
2016-2019	Professor	Psychiatry	University of Arkansas for Medical Sciences
2017-2019	Affiliate Professor	Psychiatry	University of British Columbia
2019-	Adjunct Professor	Psychiatry	University of Arkansas Medical Sciences

Appointments at Hospitals/Affiliated Institutions:

1984-1985	Clinical Staff	Psychiatry	Jewish General Hospital
1988-1992	Psychiatrist	Psychiatry	Jewish General Hospital
1989-1992	Research Psychiatrist	Child Psychiatry	Montreal Children's Hospital
1992-1993	Psychiatrist	ADHD Clinic	Vancouver General Hospital
1992-1993	Psychiatrist	Child Mood and Anxiety	University of British Columbia
1992-1993	Psychiatrist	Adult Inpatient	St. Paul's Hospital
1993-2011	Child Psychiatrist	Child Psychiatry	British Columbia Children's Hospital
1998-2003	Junior Research Scientist	Child and Family Research Institute	University of British Columbia
2003-2007	Senior Research Scientist	Child and Family Research Institute	University of British Columbia
2007-2011	Senior Research Scientist	Division of Child Psychiatry	University of British Columbia
2007-2012	Researcher	Psychiatry	University of British Columbia

2019-	Active Staff	Psychiatry	Cambridge Health Alliance
-------	--------------	------------	---------------------------

Other Professional Positions:

2012-2013	Psychiatry	Copeman Health Care
2013-2016	Psychiatry	Weiss ADHD Care

Major Administrative Leadership Positions:

Local

1989-1992	Director of Psychopharmacology	University of British Columbia
1994	Director of Outpatient Services	Department of Child Psychiatry, University of British Columbia, Vancouver
1994-2002	Director Continuing Medical Education	Division of Child Psychiatry, University of British Columbia
1998-2009	Director of Research	Division of Child Psychiatry, University of British Columbia
2003-2012	Director of the Provincial ADHD Program	Children's and Women's Health Center of British Columbia, University of British Columbia
2016-2019	Director of Child Psychiatry	University of Arkansas Medical Sciences
2016-2019	Director of Child Psychiatry	Arkansas Children's Hospital
2016-2019, 2016-2019	Director of Hospital Services	Arkansas Children's Hospital
2017-2019	Medical Director of Child Study Center	University of Arkansas Medical Sciences Arkansas Children's Hospital
2021-2022	Interim Director of Child Inpatient	Cambridge Health Alliance

Committee Service:

Local

2016	Behavioral Health Task Force	University of Arkansas for Medical Sciences, Arkansas Children's Hospital
2016	Services Task Force of Child Health Practice Plan	University of Arkansas for Medical Sciences, Arkansas Children's Hospital
Regional		
2000-2005	Clinical Research Task Force	Children's & Women's Health Centre of British Columbia, Vancouver
2007	Neuroscience Task Force	Child and Family Research Institute, Vancouver
2008	Clinical Research Council	Child and Family Research Institute, Vancouver
2008-2010	Child and Youth Advisory Committee	Mental Health Commission of Canada
2008-2010	Co-Chair Strategic Planning Committee	British Columbia Mental Health Services
2008-2010	Gender and Health Committee	Canadian Institute for Health Research
2011-2013	ADHD Task Force	Provincial Health Services Authority, British Columbia
2018	Governor's Commission on School Violence	Office of Arkansas State Governor, Asa Hutchinson
National		
2003-2010	Practice Guidelines Committee	Canadian Attention Deficit Disorder Resource Alliance
2003-2010	Practice Guidelines Committee, Member	Canadian Attention Deficit Disorder Resource Alliance (CADDRA)
2003-2014	Executive Board	Canadian Attention Deficit Disorder Resource Alliance (CADDRA)
2003-2014	Executive Board, Member	Canadian Attention Deficit Disorder Resource Alliance (CADDRA)

2014-	Advisory Council, Member	Canadian Attention Deficit Disorder Resource Alliance (CADDRA)
2014-2016	Clinical Faculty Working Group, Member	Doctors of British Columbia Committee

International

2004-2010	Advisory Board	Eli Lilly, Johnson & Johnson, Shire, Purdue, Novartis, Cingulate Therapeutics, Akili, NHS Pharma
2020-2021	Thesis review committee	Behnaz Kiana, University of Tehran, Iran, Department of Psychology
2022-	Practice Guidelines Committee	Canadian Attention Deficit Disorder Resource Alliance (CADDRA)

Professional Societies:

1988-	Fellow of the Royal College of Physicians and Surgeons, Canada, Adult Psychiatry	
1989-	American Academy of Child and Adolescent Psychiatry (AACAP)	
1989-2017	Canadian Academy of Child and Adolescent Psychiatry (CACAP)	
	1995-1998	Research Committee
1989-2018	Canadian Psychiatric Association	
1992-2016	Royal College of Physicians and Surgeons of British Columbia	
1992-2016	British Columbia Medical Association	
1992-2016	College of Physicians and Surgeons of British Columbia	
1995-1998	Canadian Academy of Child and Adolescent Psychiatry	

	1995-1998	Research Committee
	2008-2010	Scientific Program
	2011-2011	Scientific Program Committee
1997-1999	AACAP Scientific Program Committee	
2003-	Canadian Attention Deficit Disorder Resource Alliance (CADDRA)	
2006-	World Psychiatric Association	
2006-	World Psychiatric Association Section on ADHD	
2007	American Professional Society for ADHD and Related Disorders (APSARD)	
2008	Task Force on ADHD, British Columbia Pediatric Society	
2008-	World Federation of Mental Health	
2008-	World Federation of ADHD	
2008-2010	Impact ADHD	
2008-2010	CACAP Scientific Program	
2010	Colloque international de langue française sur le TDAH	
2011	APSARD Executive Board	
2011-	Scientific Program Committee, World Federation of ADHD	
2011	CACAP Scientific Program Committee	
2016-2019	Arkansas Medical Society	
2018-2020	Research and Scientific Committee	

2018-2020	American Medical Association
2019	APSARD Scientific Program Committee
2019	APSARD Advisory Council
2020-2022	Scientific program committee of the Israeli ADHD Association

Grant Review Activities:

2001	Grant review committee	Australian Research Council Grant Reviewer
2001	Grant review committee	Fédération de Recherches du Québec
2009	Grant review committee	CIHR

Editorial Activities:

Ad hoc Reviewer

Acta Psychiatrica Scandinavica Journal

American Family Physician

American Journal of Psychiatry

Archives of Pediatrics and Adolescent Medicine

Behavioral and Brain Functions

Behavioral Sleep Medicine Journal

Biological Psychiatry Journal

Brain Sciences

Canadian Journal of Psychiatry | Canadian Psychiatric Association

Child and Adolescent Psychiatry and Mental Health | International Association for Child and Adolescent Psychiatry and Allied Professions

Child Neuropsychology | American Academy of Clinical Neuropsychology Pediatric

CNS Drugs Journal | Springer

CNS Spectrum Journal | Cambridge University Press

Current Opinion in Pediatrics Journal

Current Opinion in Psychiatry Journal

Developmental Medicine and Child Neurology Journal | American Academy for Cerebral Palsy and Developmental Medicine

Drugs of the Future Journal

Epilepsy and Behavior Journal

European Child & Adolescent Psychiatry Journal | Springer Nature Switzerland

European Journal of Pediatric Neurology Journal | European Paediatric Neurology Society

European Neuropharmacology Journal | European College of Neuropsychopharmacology

European Psychiatry Journal | European Psychiatric Association

Expert Opinion on Drug Metabolism and Toxicology Journal

Expert Review of Neuro-therapeutics Journal | Informa UK Limited

Expert Opinion on Pharmacotherapy Journal | Informa UK Limited

Frontiers in Psychiatry

IEEE Journal of Biomedical and Health Informatics

Journal of Abnormal Psychology | American Psychology Association

Journal of Affective Disorders | Official Journal of the International Society for Affective Disorders

Journal American Academy of Pediatrics

Journal of American Medical Association

Journal of American Medical Association of Pediatrics

Journal of Attention Disorders | The American Professional Society of ADHD and Related Disorders

Journal of Behavioral Pediatrics | Official Journal of the Society for Developmental and Behavioral Pediatrics

Journal of Behavior Therapy and Experimental Psychiatry | Journal of Experimental Psychopathology

Journal of Clinical Psychiatry | American Society of Clinical Psychopharmacology (ASCP)

Journal of Clinical Psychology & Psychotherapy

Journal of Clinical Medicine

Journal of the American Academy of Child and Adolescent Psychiatry

Journal of Child and Adolescent Psychopharmacology

Journal of Comparative Effectiveness Research

Journal of Psychology and Psychiatry | Association for Child and Adolescent Mental Health

Journal of the Canadian Academy of Child and Adolescent Psychiatry

Journal on Mental Illness | PAGE Press, Pavia, Italy

Lancet Psychiatry Journal

New England Journal of Medicine | Massachusetts Medical Society

Nordic Journal of Psychiatry

Pediatrics

Pediatrics and Child Health | Canadian Pediatric Society

Pharmacoepidemiology and Drug Safety | International Society for Pharmacoepidemiology

Pharmaceutical Medicine Journal | Springer

Progress in Neuro-Psychopharmacology and Biological Psychiatry, An International Research and Reviews Journal

Psychiatry Research Journal | Elsevier

Psychological Medicine Journal | Cambridge University Press

Theoretical Biology and Medical Biology and Medical Modeling | Springer Nature

Quality of Life Research Journal

Clinical Child Psychology and Psychiatry

Journal of Psychiatric Research

Other Editorial Roles

1996-	Editorial Board	Journal of Attention Disorders
2004	Guest editor and reviewer	Advances in the treatment of adult ADHD, Medscape
2007-2012	Editorial Board	World Journal of Pharmacology
2007-2012	Editorial Board	International Journal of Pediatrics and Child Health
2011-2019	Editorial Board	World Journal of Psychiatry
2018	Editorial Board	Attention Deficit Hyperactivity Disorder

Honors and Prizes:

1976	Lila Pearlman Memorial Award	Brandeis University	Award to an outstanding student in the Field of History
1976	Magna cum laude	Brandeis University	Highest honors in History
1976-1983	Canada Council Award, PhD	Canada Council	Financial support to complete PhD
1976-1983	PhD Bursary	Fédération de Recherches du Québec	Financial support to complete PhD
1983	Logie Medical Ethics Prize	Canadian Medical Association	National contest for the best essay in the field of ethics.
1983	Mona Bronfman Schekman Prize in Psychiatry	McGill University	Awarded to the student with the highest academic standing in Psychiatry
1986	Wyeth Prize to a Psychiatric Resident	McGill University	

1987	Saul Wilner Memorial award to a Psychiatric Resident	McGill University	
2004	Clinical Scientist Award	BC Research Institute	Financial support to conduct research in psychiatry.
2005, 2006	Master Clinician	American Academy of Child and Adolescent Psychiatry	
2006	Elaine Schlosser Lewis Award	American Academy of Child and Adolescent Psychiatry	Prize for the best research paper in ADHD published in the journal that year.
2007	Best Research Paper	Canadian Academy of Child and Adolescent Psychiatry	
2009	Award for the Best Poster	World Federation of ADHD	2nd International Congress in ADHD, Vienna 2009
2010	TRICEPS Award	University of British Columbia	Faculty member who excels in Translating Research in Clinical Excellence in Psychiatric Settings
2018	Richard L. Livingston Award for Excellence in Resident Education	University of Arkansas Medical Sciences	Faculty award for best resident teaching in psychiatry.
2022	CHA Academic Council Award	Cambridge Health Alliance	Cambridge Health Alliance award for academic excellence and achievement.

Report of Funded and Unfunded Projects

Past

1988-2001 Psychopathology in Offspring of Mothers with Borderline Personality Disorder: A Pilot Study
Mortimer B. Davis Jewish General Hospital Research Award; Peer Reviewed PI (\$20,295)
High-risk follow-up study to determine if children of mothers with borderline

personality disorder (BPD) are at risk for psychopathology, particularly impulse spectrum disorders.

- 1994-1995 **Attributions in ADHD**
British Columbia Research Foundation; Peer reviewed competitive grant
Co-Investigator (PI: Charlotte Johnston, \$67,398)
To study parent attributions regarding ADHD in offspring.
- 1997-2000 **Maintenance therapy for adolescent depression.**
Medical Research Council of Canada; Peer reviewed, competitive grant.
Site Co-Principal Investigator (Co-PI: Anthony Levitt)
Outcome of a randomized discontinuation trial.
- 1998-2000 **Sleep Hygiene and Melatonin Treatment for Children and Adolescents with ADHD and Initial Insomnia**
Centre for Complementary Medicine and Circa Dia; Peer Reviewed, ERIC Number EJ754408
PI (\$252,000)
This was a randomized clinical trial to evaluate the efficacy of sleep hygiene and melatonin treatment for initial insomnia in children with attention-deficit/hyperactivity disorder (ADHD).
- 1999-2002 **A Randomized Double-Blind Trial of Paroxetine and/or Dextroamphetamine and Problem-Focused Therapy for Attention Deficit/Hyperactivity Disorder in Adults**
GlaxoSmithKline; Interventional
GSK#707
PI (\$507,000)
This was a randomized clinical trial to determine the effect of psychotherapy, dextroamphetamine, and/or paroxetine on attention-deficit/hyperactivity-disorder (ADHD) and mood/anxiety in adults
- 2001-2003 **Efficacy and Safety of Ritalin LA, a New Once Daily, Extended-Release Dosage Form of Methylphenidate, in Children with Attention Deficit Hyperactivity Disorder**
Novartis; Interventional
Site PI
To evaluate the safety and efficacy of extended-release methylphenidate with a bimodal profile using SODAS technology (Ritalin LA) compared with placebo in children aged 6-14 years with attention deficit hyperactivity disorder (ADHD).

- 2003-2005 Guiding Dose Increases In Patients Incompletely Responsive to Usual Doses of Atomoxetine by Determining Plasma Atomoxetine Concentrations: a Randomized, Double-Blind Study
Eli Lilly; Interventional
NCT00485407
8226
B4Z-MC-LYCL
Co-PI (Co-PI: Chris Kratochvil)
Test whether patients treated with atomoxetine 1.2 mg/kg/day who have sub-optimal clinical responses and peak plasma atomoxetine levels no higher than 800 ng/mL will benefit from a dose increase to 2.4 mg/kg/day.
- 2003-2011 Advanced Neuroimaging: Ethical, Legal and Social Issues
Qualitative
NIH Project # 9R01MH084282-04A1
Co-PI (Co-PI: Dr. Ills)
Qualitative study to identify and address the interactions of research with ethics and society at its earliest stages.
- 2004-2006 A Phase IIIb Open-Label Trial of Atomoxetine Hydrochloride to Evaluate Academic Outcome in Children Ages 8 to 11 Years With Attention-Deficit/Hyperactivity Disorder
Eli Lilly; Interventional
NCT00191880
7649
B4Z-CA-LYCS
Co-PI (Co-PI: Ruth Dickson)
The primary objective of this study is to assess the correlation of change from baseline to one year in ADHD symptoms as measured by the Attention Deficit/Hyperactivity Disorder Rating Scale- IV-
- 2004-2006 Atomoxetine Treatment of Adults With ADHD and Comorbid Alcohol Abuse: A Randomized, Placebo-Controlled Trial
Eli Lilly; Interventional
NCT00190957
7069
B4Z-MC-LYBY
Site PI (PI: Tim Wilens)
To test that atomoxetine is superior to placebo in reducing ADHD severity as measured by the Adult ADHD Investigator Symptom Rating Scale (AISRS) Total score and is superior to placebo in time to relapse of alcohol abuse at 12 weeks.

- 2004-2006 Once-daily multilayer-release methylphenidate in a double blind, crossover comparison to immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder
Purdue Pharma; Interventional
PI
To evaluate the comparative efficacy and safety of a novel long-duration multilayer (MLR) methylphenidate (MPH) formulation and immediate-release (IR) MPH with attention-deficit/hyperactivity disorder.
- 2004-2009 Inattention, Working Memory, and Academic Achievement in Adolescents Referred for Attention Deficit/Hyperactivity Disorder (ADHD)
Canadian Institute for Health Research (CIHR); Psychological, Experimental, Peer Reviewed Competitive Grant from CIHR # MOP 64312
Co-Investigator (PI: Charlotte Johnston, \$170,0i00)
To investigate the role of inattention and working memory in predicting academic achievement in adolescents aged 13-18 referred for Attention Deficit/Hyperactivity Disorder (ADHD).
- 2005-2006 A 3 Month Open-Label Study of Atomoxetine in Children With Attention-Deficit/Hyperactivity Disorder; Symptomatic and Functional Outcomes
Eli Lilly; Interventional clinical trial. NCT00191633
9684
B4Z-CA-S012
Site PI
To assess the correlation of change in score on an ADHD rating scale with the change in score on a functional rating questionnaire at 3 months post atomoxetine initiation. Understand the relationships between ADHD symptoms, functional outcomes, and quality of life. Use data collected to validate the WFIRS-P questionnaire.
- 2005-2006 An Open-Label Pilot Study of Atomoxetine Hydrochloride to Evaluate Neuropsychological Function in Children Ages 6 to 10 Years With Attention-Deficit/Hyperactivity Disorder.
Eli Lilly; Open label, interventional trial
NCT00216918
B4Z-CA-S013
Site PI
The neuropsychological status in five domains as measured by the change in the NEPSY from baseline to 6 months post-initiation of atomoxetine treatment in children ages 6 to 10.5 diagnosed with ADHD. Assess the relationships of change from baseline to approximately 2 and 6 months, or

endpoint in the core symptoms of ADHD with the changes in functional outcomes as assessed by the WFIRS-P.

- 2005-2007 Efficacy of a Novel Biphasic Controlled-Release Methylphenidate Formula in Adults with Attention-Deficit/Hyperactivity Disorder: Results of a Double-Blind, Placebo-Controlled Crossover Study
Purdue Pharma; Interventional clinical trial
Co-PI (Co-PI: Graeme Donnelly)
To evaluate the efficacy and safety of a new biphasic multilayer (MLR) methylphenidate formulation in a double blind, placebo-controlled crossover study in adults with attention-deficit/hyperactivity disorder (ADHD).
- 2005-2008 A naturalistic prospective one year follow up study of effectiveness outcomes in children and adolescents with ADHD
Janssen-Ortho; Investigator initiated, industry sponsored
trialClinicalTrials.gov Identifier: NCT00307268, Other Study ID: H05-70361
PI (\$250,000)
The goal was to evaluate change over two years of treatment of usual in an ADHD clinic setting.
- 2005-2008 Evaluating clinical outcomes of treatment effectiveness for children and adolescents with ADHD: an observational, long-term follow-up study of routine clinical care
Eli Lilly; Investigator initiated, industry sponsored grant. ClinicalTrials.gov Identifier: NCT00307268, Other Study ID: H05-70361
PI (\$195,000)
Effectiveness outcomes of treatment as usual over two years of treatment in children and youth with ADHD from 6 - 18 years of age.
- 2005-2009 Improving the accuracy of parents' reporting of child attention deficit/hyperactivity disorder
CIHR; Peer reviewed, competitive
Investigator (PI: Charlotte Johnston)
To determine if a brief educational intervention improves accuracy of symptom report.
- 2005-2009 The Effects of Instructions on Mothers' Ratings of Child Attention-Deficit/Hyperactivity Disorders Symptoms
Psychological, Experimental, Canadian Institute for Health Research (CIHR)
Co-Investigator (PI: Charlotte Johnston)
Examination of instructional materials describing how to rate child ADHD

symptoms would improve the accuracy of mothers' ratings of ADHD symptoms presented in standard child behavior stimuli.

- 2005-2011 Long-Term, Open Label Atomoxetine Study
Eli Lilly; Interventional Open label follow-up, ClinicalTrials.gov Identifier: NCT00190684, Other Study ID: B4Z-MC-LYAI
Site PI (PI: A.)
To learn about the safety and any side effects of atomoxetine when given to children and adolescents for about 5 years (long-term) and to learn whether atomoxetine can help children and adolescents with attention-deficit/hyperactivity disorder (ADHD) who take the drug for about 5 years (long-term).
- 2006-2007 Dietary Intake and Nutrient Status of Children with ADHD
Danone Institute and Eli Lilly and Company; Investigator initiated, industry sponsored study H05-70464, W05-0185,
PI (\$35,000)
Exploratory open label study to assess the dietary intake of children aged 6-12 years by means of a 24-hour recall and 3-day food record and assess the nutrient status of Vitamin B6, serum zinc and serum copper of the same children by means of standard laboratory assessments.
- 2006-2010 Do People With ADHD, Who Respond Well to Amphetamine Medication but not to Methylphenidate, Have Allelic Variants of the SNAP 25 Gene?
UBC Human Early Learning Partnership (HELP); ClinicalTrials.gov Identifier: NCT00885560, Other Study ID: H05-7410
PI (\$5,000)
To enhance our capacity to correctly choose the appropriate medication for ADHD patients on the first try based on the presence of a particular variant of a gene that could be identified on a laboratory test.
- 2006-2011 A Prospective Chart Review to Validate the WFIRS (Weiss Functional Impairment Rating Scale)
Psychometric Study, Investigator Initiated Industry Sponsored by Eli Lilly, Purdue Pharma and Shire Pharmaceuticals; ClinicalTrials.gov Identifier: NCT00885807, Other Study ID: H05-70402,
PI (\$10,000)
This was a psychometric validation of the Weiss Functional Impairment Rating Scale.
- 2006-2011 The Effectiveness of CONCERTA vs. Usual Clinical Care With Immediate Release Methylphenidate (IR MPH) in Children (6-12 Years) With Attention Deficit Hyperactivity Disorder (ADHD): A Randomized, Open-Label Trial

Janssen-Ortho; Interventional

NCT0030468

CR003112

Co-PI (Co-PI: Margaret Steele)

The purpose of this study is to determine the effectiveness and safety of OROS*methylphenidate/CONCERTA* vs. immediate release methylphenidate as a treatment for ADHD specifically for those children who have behavioral difficulties in the afternoon/after-school and evening periods.

2009-2010

Tolerability and Efficacy of AM and PM A Phase 3, Double-blind, Randomized, Multicenter, Placebo-controlled, Dose Optimization Study Evaluating the Tolerability and Efficacy of AM and PM Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Children Aged 6-12 With a Diagnosis of Attention-Deficit/Hyperactivity Disorder

Shire; Interventional

NCT00997984

SPD503-314

Site PI (PI: Jeffrey Newcorn)

The primary purpose is to assess the efficacy of once daily dosing with optimized SPD503 (1, 2, 3 and 4mg/day), dosed either in the morning or evening, compared to placebo, in children with ADHD as measured by change from baseline score at endpoint on the ADHD-RS-IV.

2010-2014

A Phase 3, Double-blind, Placebo-controlled, Multicentre, Randomised Withdrawal, Long-term Maintenance of Efficacy and Safety Study of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 With Attention Deficit/Hyperactivity Disorder

Shire; NCT01081145

SPD503-315

Site PI

The primary objective of this study is to evaluate the long-term maintenance of efficacy of Extended-Release Guanfacine HCl in children and adolescents (6-17 years) with attention-deficit/hyperactivity disorder (ADHD) who respond to an initial open-label, short term treatment with SPD503.

2010-2014

Attention-Deficit/Hyperactivity Disorder Symptoms in Mothers and Fathers: Family Level Interactions in Relation to Parenting

Canadian Institute for Health Research (CIHR); Peer reviewed competitive grant CIHR MOP 106586

Co-Investigator (PI: Charlotte Johnston)

Multiple psychological experiments looking at the impact of ADHD in parents on parenting.

2014-2015 A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Multi-Center Study Measuring the Efficacy and Safety of PRC-063 in Adolescent ADHD Patients
Purdue Pharma; NCT02139111
063-009
PI
The purpose of this randomized, placebo-controlled, double-blind, parallel group study is to evaluate the clinical efficacy and safety of PRC-063 in adolescents with ADHD.

2014-2015 A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Multi-Center Study Measuring the Efficacy and Safety of PRC-063 in Adult ADHD Patients
PI
The purpose of this randomized, placebo-controlled, double-blind, parallel group study is to evaluate the clinical efficacy and safety of PRC-063 in adults with ADHD.

2014-2015 A Six-month, Open-label, Multi-center Study of the Safety and Efficacy of PRC-063 in Adults and Adolescents With ADHD
Purdue Pharma; Interventional clinical trial
NCT02168127
063-012
PI (PI: Margaret Weiss)
The purpose of this six month, open-label study is to evaluate the long-term safety and efficacy of PRC-063 in adults and adolescents with ADHD.

2016-2018 Effects of Low-Dose Psychostimulants on Executive Functions in Children With ADHD
Vancouver Coastal Health Research Institute; Psychological Experiment
Co-PI (Co-PI: Adele Diamond, \$49,993)
To examine the impact of low vs. high dose stimulant on working memory testing.

Current

2021-2025 Early Screening and Treatment of High-Risk Youth (eSToRY)
NIMH; Methods Core (1P50MH126283-01)
Investigator (PI: Benjamin Cook)
The objective of E-SToRY is to better identify and understand disparities in

mental health for youth at risk. The objective of the methods core is to seamlessly integrate large administrative datasets and integrate input from clinical and services researchers and community stakeholders.

2021-2025 Prevention and Early Identification for High-Risk Youth in School Based Clinics
 NIMH; R34 (1P50MH126283-01)
 PI (\$1,350,000)
 The research project provides a novel approach to screening, early assessment, and preventive interventions for high-risk youth in race, ethnicity and language diverse communities.

Projects Submitted for Funding

2022 Effectiveness and Safety of Psychotropic Medications for Youth with Intellectual Disability
 Patient-Centered Outcomes Research Institute (PCORI); Peer reviewed, competitive
 PI (\$2,833,324.00)
 This is a naturalistic, prospective study to compare outcomes among children and youth with Intellectual and Developmental Disabilities in a safety net system across the following medication interventions: antipsychotics vs. alpha agonists and antipsychotics plus adjunctive antidepressants. The study will look at real life effectiveness outcomes including symptoms and behavior, aggression, functional impairment, quality of life, and safety. All outcomes will look at whether social determinants of health and race, ethnicity and language moderate the findings.

Report of Local Teaching and Training

Teaching of Students in Courses:

1976-1978	Introduction to the History of Sciences Teaching Assistant	History of Science, Harvard University 1 hour / week.
1977-1978	History of Public Health in 19th Century America Teaching Assistant	School of Public Health 1 hour / week.
1989-1991	Behavior Science Course, Faculty of Medicine Medicine, First year Medical Students	McGill University 4 hours / week

Formal Teaching of Residents, Clinical Fellows and Research Fellows (post-docs):

1989-1992	Psychotherapy Course, Short Term Psychiatry Residents	McGill University 1 hour / week
1990-1992	Bipolar Illness Seminar Residents Diploma Course	McGill University 4 hours / year.
1993-2012	Psychopharmacology Course Psychiatry Residents	University of British Columbia 25 hours / year. .1 hr/week, year long
2016-2019	Didactic lectures residents and fellows Psychiatry Residents	University of Arkansas for Medical Sciences, 12 hrs/week 8 hours / year.
2019-2021	Psychopharmacology course for child fellows: lectures on anxiety, aggression ADHD, depression, OCD, schizophrenia, bipolar, PTSD	Cambridge Health Alliance: 1hr/week, year long 3 hours / year.
2021-	Developed new lecture curriculum for Child and Adolescent Fellows Year 1: Research Informed Clinical Assessment and Treatment of Emotional and Behavior Disorders in Children First year child fellows	Cambridge Health Alliance 52 hours / year.

Clinical Supervisory and Training Responsibilities:

1989-1992, 1989-1992	Supervision of Psychiatry Residents in Psychopharmacology Child psychiatry fellows.	University of British Columbia 5 hours / week
1991-1992	Supervision First year child fellows.	McGill University 5 hours / week
1991-1992	Supervision Psychiatry residents.	McGill University 5 hours / week
2016-2018	Supervision Child fellows and psychiatry residents.	University of Arkansas for Medical Sciences 7 hours / week

2016-2018	Supervision Psychiatry residents.	University of Arkansas for Medical Sciences 7 hours / week
2016-2019	Supervision Child fellows and junior attending.	University of Arkansas for Medical Sciences 7 hours / week
2016-2019	Supervision Child fellows and junior attending.	University of Arkansas for Medical Sciences 6 hours / week
2019-	Supervision Child psychiatry fellows.	Cambridge Health Alliance 3 hours / week
2019-	Supervision Residents and Fellows in Child Psychiatry.	Cambridge Health Alliance 3 hours / week

Research Supervisory and Training Responsibilities:

1991-1992	Supervisor Two research fellows in affective disorders.	McGill 2 hours / week
1993-2012	ADHD Fellowship International Research Fellow from China International fellows (pediatrics)	University of British Columbia 12 hours / week
1993-2012	ADHD Fellowship Research Fellow ADHD research fellows	University of British Columbia 0.4 hours / week. .4
1993-2012	Supervision ADHD research fellow	University of British Columbia 0.4 hours / week. .4 hrs/week, full year course
2016-2019	Child Academic Track, Research Mentorship Child psychiatry fellows.	University of Arkansas for Medical Sciences 3 hours / week

2017-2019	NARSAD Research Grant, Research Mentorship (National Alliance in Schizophrenia and Affective Disorders) Neuropsychology researcher	University of Arkansas for Medical Sciences 1 hour / week
2021-	Eleanor Richards Learning Scholar Award Junior psychology researcher	Cambridge Health Alliance 2 hours / week

Other Mentored Trainees and Faculty:

1996-1997	S. Myckatyn, MD. Psychiatry resident funded under a CIHR bursary. Supervision in publication, academic activity, and research. Learned how to do a literature review, publication skills, and basic principles of research.	
1998-1999	Cynthia Chan, MD. Child psychiatry trainee under a CIHR bursary. Supervision in publication, academic activity, and research. Cynthia Chan, Child psychiatry trainee under a CIHR bursary.	
1998-2005	Melissa Bomben, MA. Research scientist and research associate. Melissa was running our research operations. Multiple publications.	
2000-2001	Sunita Maria Nayer, MD. CIHR psychiatry trainee with a CIHR research bursary. I provided research and general academic mentorship. Went on to do clinical work.	
2000-2002	Leanne Mak, PhD psychology graduate student. Mentored her in research skills and publication. Went on to do several research projects at BC Children's Hospital	
2000-2005	Candice Murray, PhD. Managing Director of Psychology at Children's and Women's Health Centre, Vancouver Supervision in publication, academic activity, and research while a graduate student and then as junior staff. Now a collaborator on University of British Columbia research study of stimulant medication and executive functions. Candice became a national leader in adult ADHD and authored several publications.	
2000-2005	Dr. Michael Wasdell, MA. Ontario HIV Treatment Network data scientist Master's level data scientist and grants facilitator working in the Mental	

Health Research Unit mentored in clinical trials and behavioral health research.

We collaborated together on several research projects and publications. He is now Director, Evidence Impact at Ontario HIV Treatment Network.

- 2001 Benjamin Steinberg, MD PhD. CIHR Bursary. Hospital for Sick Children, University of Toronto.
PhD student mentored in basic research skills.
Research experience led to his becoming a Scientist-Track Investigator in the Program in Neuroscience and Mental Health, at The Hospital for Sick Children.
- 2001-2002 Michelle Ngo, PhD. CIHR Bursary. Now a pediatrician.
Pediatrics resident mentored in publication, academic and research activities.
Clinical practice.
- 2004-2010 Joy Kiddie, MA. Now a nutritionist running Better by Design Nutrition.
Master student mentored on research and publication of Master's dissertation.
Publication in 2010.
- 2005-2006 Julie Hunter, MD. Clinical practice psychiatry.
Research fellow with supervision in publication, academic activity, and research.
Publication in 2007.
- 2006-2007 Carolyn Jang, MD. CIHR research bursary.
MD pediatric resident developing research literacy.
Clinical practice.
- 2006-2009 Chris Gibbins, PhD. Currently in private practice as a clinical psychologist specializing in autism.
Junior clinical psychologist whom I supervised with publication, academic, and research activities.
Collaborated on 9 research publications.
- 2007-2010 Li Ying Lu, MD. Director pediatrics, Hunan province.
Leading pediatrician in China who came for a 3-year fellowship to learn how to set up a tertiary clinic and to gain experience doing research in ADHD.
She set up an ADHD clinic in China using the model of what she had learned in Vancouver/
- 2008-2008 Maria Arranzlim, MD. Child psychiatrist in the Philippines.
Preceptorship and visiting scholar to the ADHD clinic to learn more about our

clinical research unit.

She returned to the Philippines to set up an ADHD center of excellence modeled on what she saw in Vancouver.

- 2008-2008 Jyoti Bhagia, MD. Project Leader Service Excellence Collaborative, ADHD Clinic, Division of Child and Adolescent Psychiatry and Psychology
Child psychiatrist looking to learn more about how to set up a tertiary clinic. She modeled the ADHD clinic at Mayo on things she saw at our unit.
- 2011-2011 Ando Mizuho, MD. Professor in Psychology and researcher in ADHD at University of Tsukuba, Japan.
Preceptorship and visiting scholar to the ADHD clinic to learn more about our clinical research unit.
Supervision in publication, academic activity, and research.
- 2011-2011 Toshiba Takeda, MD. Professor in psychology and researcher in ADHD at University of Tsukuba, Japan.
Preceptorship and visiting scholar to the ADHD clinic to learn more about our clinical research unit.
Supervision in publication, academic activity, and research.
- 2014-2015 Dr. Stephanie Craig, PhD. Dr. Stephanie Craig is a Research Associate in the LaMarsh Centre for Child and Youth Research and a Post-Doctoral Fellow in the Lassonde School of Engineering at York University.
Psychology Intern doing her Clinical and Research Placement and then supervised her postdoctoral work.
Currently a Research Associate in the LaMarsh Centre for Child and Youth Research and a Post-Doctoral Fellow in the Lassonde School of Engineering at York University. We have multiple publications together.
- 2017 Dr. Behnaz Kiani, PhD. Research psychologist at the University of Tehran.
PhD psychology student at Tehran University supervised on her doctoral dissertation, and multiple publications.
Active research and 3 recent peer reviewed publications.
- 2017-2019 Dr. Meredith Addicott, PhD. NARSAD grant supervisor.
Junior research faculty, supervised on her NARSAD grant working with adults with ADHD.
Publication in 2019. NIDA funded researcher at University of Arkansas Medical Sciences.
- 2021-2022 Dr. Eleanor Richards, PhD, Learning Health Scholar, Cambridge Health Alliance

Dr. Richards is a clinical psychologist who is a Learning Health Scholar mentored on publication of a study of access to mental health services high school. She is also a collaborator as a co-investigator on our NIMH grant. She has done grand rounds, and the publication of this study is in preparation.

Formal Teaching of Peers (e.g., CME and other continuing education courses):

No presentations below were sponsored by 3rd parties/outside entities

1993-2012	GP Course on Adult ADHD, CME Course ADHD in Adults, University of British Columbia	Single Presentation British Columbia, Canada
2014	ADHD in Adults, CME on the Run! University of British Columbia	Single Presentation Vancouver, BC

Local Invited Presentations:

Those presentations below sponsored by outside entities are so noted and the sponsor(s) is (are) identified.

2006	An Overview of ADHD: A Provincial Perspective. / Grand Rounds Children's and Women's Health Center, University of British Columbia.
2007	ADHD and Sleep. / Invited Lecture Department of Pediatrics, University of British Columbia.
2007	Essentials of ADHD / Invited Lecture Second Annual Child Psychiatry Workshop, BC Children's Hospital
2008	ADHD in Adults. / Grand Rounds Forensic Grand Rounds, Forensic Psychiatry Services, British Columbia, Canada
2008	Diagnosis and Treatment of the Adult with ADHD / Invited Lecture Hot Topics in Psychiatry, University of British Columbia CME
2008	Everything You Always Wanted to Know About ADHD But Were Afraid to Ask / Invited Lecture Postgraduate Review of Medicine.
2008	Optimizing and Individualizing Treatment of ADHD; Pediatric Grand Rounds, / Grand Rounds Pediatric Grand Rounds, University of British Columbia

- 2017 New Perspectives on ADHD / Grand Rounds
Grand Rounds Child Division, Arkansas Children's Hospital Rock
Arkansas, United States
- 2018 Online Assessment of Symptoms and Functioning; / Grand Rounds
Grand Rounds, Child Psychiatry, University of Arkansas for Medical
Sciences
- 2019 Stimulant Treatment of Adult ADHD / Grand Rounds
Psychiatry Grand Rounds, Cambridge Health Alliance
- 2019 The Complex Interface of ADHD and Sleep, Pediatric Grand Rounds /
Grand Rounds
Boston Children's Hospital

Report of Regional, National and International Invited Teaching and Presentations

Those presentations below sponsored by outside entities are so noted and the sponsor(s) is (are) identified.

Regional

- 2008 Pharmacology of Adult ADHD; Grand Rounds Royal Jubilee Hospital /
Invited Lecture
Victoria, British Columbia, Canada
- 2011 ADHD and Sleep / Invited Lecture
BC Pediatric Society; Vancouver, British Columbia
- 2011 Hyperactive Sleep / Invited Lecture
British Columbia Pediatric Society, British Columbia, Canada
- 2012 A Step-to-Step Guide for Treatment of ADHD / Invited Lecture
Kelowna, British Columbia, Canada, Janssen
- 2012 ADHD in Adulthood / Invited Lecture
Academic Rounds, Surrey Memorial Hospital; Vancouver, British Columbia,
Canada
- 2012 ADHD in Adults: Establishing Service; Ministry of Children & Family
Development / Invited Lecture
Vernon, British Columbia, Canada

- 2012 ADHD in Family Practice / Invited Lecture
Vancouver, British Columbia, Canada
- 2012 Motor Vehicle Accident Syndrome / Invited Lecture
Continuing Legal Education Society of British, British Columbia, Canada
- 2013 ADHD and Sleep / Invited Lecture
Kelowna, British Columbia, Canada
- 2013 Beyond Medical Necessity / Invited Lecture
BC Law Society, Vancouver, British Columbia, Canada
- 2013 Treatment of ADHD / Invited Lecture
Kelowna, British Columbia, Canada
- 2014 ADHD Across the Lifespan; Spall Medical Clinic / Invited Lecture
Kelowna, British Columbia, Canada
- 2014 ADHD and Sleep, Eli Lilly / Invited Lecture
Kelowna, British Columbia, Canada
Vernon, British Columbia, Canada
- 2014 ADHD in Adults / Invited Lecture
Hot Topics and Practical Approaches in Mental Health, British Columbia,
Canada
- 2015 Executive Function in the Classroom (workshop), BC Teachers Professional
Day / Workshop
Vancouver, British Columbia, Canada
- 2015 Executive Function in the Classroom, BC Teachers Professional Day /
Workshop
Vancouver, British Columbia, Canada
- 2015 Online Assessment: Canadian Attention Deficit Resource Alliance / Invited
Lecture
Vancouver, British Columbia, Canada
- 2015 Pay Attention! And We Will Show You How; Canadian Attention Deficit
Resource Alliance / Invited Lecture
Vancouver, British Columbia, Canada

2015 Training ADHD in Adults; Vancouver General Hospital Grand Rounds / Grand Rounds
Vancouver, British Columbia, Canada

2021 Managing autism in the schools / Invited Lecture
Cambridge Health Alliance Continuing Medical Education

National

2003 A New Era in The Management of ADHD: New Practice Guidelines, Medications, and Approaches to Differential Diagnosis; Canadian Psychiatric Association 53rd Annual / Invited Lecture
Halifax, Nova Scotia, Canada

2004 Clinical Implications of New Research in ADHD; Satellite Symposium to the Canadian Psychiatric Association / Symposium
Montreal, QC, Canada

2004 Update on ADHD in adults; Canadian Psychiatric Association 54th Annual Meeting / Invited Lecture
Montreal, QC, Canada

2006 ADHD in Adults; Canadian Psychiatric Association 56th Annual Meeting / Invited Lecture
Toronto, Ontario, Canada

2006 Sleep and ADHD; Canadian Academy of Child and Adolescent Psychiatry 26th Annual Meeting / Invited Lecture
Toronto, Ontario, Canada

2006 TDAH (ADHD). Invited speaker at Sacre Coeur, Hospital Riviere des Prairies et Robert Giffard, Quebec City, QC; Douglas Hospital, Montreal, QC; St. / Invited Lecture
Quebec, Purdue Pharma.

2006 Trouble de déficit de l'attention avec/sans hyperactivité, Université Laval
Quebec City, QC, Canada

2006 Understanding Adult ADHD, Novel Treatments for ADHD; Canadian ADHD Resource Alliance / Invited Lecture
Toronto, Ontario, Canada

- 2008 Consultation Café; Canadian Academy of Child and Adolescent Psychiatry Annual Meeting / Symposium
Vancouver, British Columbia, Canada
- 2008 Economic Cost of ADHD / Invited Lecture
Canadian Attention Deficit Disorder Association
- 2008 Engaging the Family in Treatment of ADHD; CADDRA Annual Conference / Invited Lecture
Toronto, Ontario, Canada
- 2008 Health Care Costs of ADHD; Canadian Attention Deficit Disorder Advocacy / Invited Lecture
Vancouver, British Columbia, Canada
- 2008 Moving Beyond Core Symptoms, Plenary Address; CADDRA Annual Conference / Invited Lecture
Toronto, Ontario, Canada
- 2008 New Research in Medication Treatment of ADHD; Canadian Academy of Child and Adolescent Psychiatry / Invited Lecture
Vancouver, British Columbia, Canada
- 2008 New Research in Medication Treatment of ADHD; Canadian Academy of Child and Adolescent Psychiatry Annual Meeting / Invited Lecture
Vancouver, British Columbia, Canada
- 2008 Optimizing and Individualizing Treatment Outcome for ADHD; Grand Rounds, Glenrose Hospital / Grand Rounds
Edmonton, Alberta, Canada, Eli Lilly
- 2008 Taking the Fear Out of ADHD Medication; CADDRA Annual Conference / Invited Lecture
Toronto, Ontario, Canada
- 2009 ADHD Treatments: What Does the Future Hold? CADDRA 2009 ADHD Conference / Invited Lecture
Montreal, QC, Canada
- 2009 Administrative and Advocacy Issues in Relation to Government; Canadian Academy of Child and Adolescent Psychiatry 29th Annual Meeting / Invited Lecture
Toronto, Ontario, Canada

- 2009 Iron, Zinc, and Other Trace Minerals in Developmental Psychopathology; 56th Annual Meeting / Invited Lecture
American Academy of Child and Adolescent Psychiatry, Honolulu, Hawaii, United States
- 2009 Les traitements du TDAH: Que Réserve l'avenir; CADDRA 2009 ADHD Conference / Invited Lecture
Montreal, QC, Canada
- 2009 Treatment Resistant ADHD; CADDRA 2009 ADHD Conference / Invited Lecture
Montreal, QC, Canada
- 2010 Comorbidity and Differential Diagnosis in Adults with ADHD; Canadian Academy of Child and Adolescent Psychiatry 30th Annual Meeting / Symposium
Toronto, Ontario, Canada
- 2010 Nutrition in ADHD; Canadian Academy of Child and Adolescent Psychiatry 30th Annual Meeting / Invited Lecture
Toronto, Ontario, Canada
- 2010 The Many Faces of ADHD / Invited Lecture
Canadian Attention Deficit Disorder Resource Alliance (CADDRA) Annual Meeting
- 2011 Guide to the ADHD Toolkit; Canadian Attention Disorder Resource Alliance Annual Meeting / Symposium
Toronto, Ontario, Canada
- 2011 Psychoeducation of The Patient and The Caregiver; Canadian Attention Disorder Resource Alliance Annual Meeting / Invited Lecture
Toronto, Ontario, Canada
- 2012 TDAH: Traitements Pharmacologiques, Plenary Session; Atelier: TDAH, sommeil, alimentation et poids / Invited Lecture
Québec, Québec, Canada
- 2013 ADHD & the Brain: Understanding ADHD in Children and Adolescents / Invited Lecture
Canadian Attention Deficit Disorder Association of Canada (CADDAC), Toronto, Ontario, Canada

- 2013 ADHD and Learning, ADHD in Elementary Schools; / Invited Lecture
Centre for ADHD Awareness, Canada, (CADDAC) Conference for
Educators, Ontario, Canada
- 2013 ADHD and Sleep Disorders; Montreal Children's Hospital / Grand Rounds
Montreal, Quebec City, Canada
- 2013 Adult ADHD; Foothills Hospital, Eli Lilly / Grand Rounds
Calgary, Alberta, Canada
- 2013 Pediatric Sleep Disorders / Invited Lecture
Edmonton, Alberta, Canada
- 2013 Rethinking ADHD as an Adult Disorder, Public Lecture / Invited Lecture
CADDAC, Toronto, Ontario, Canada
- 2013 Sommeil et TDAH – Réunion des Pédiatres et Pédopsychiatres: TDAH /
Invited Lecture
Québec, QC, Canada
- 2013 What Health Care and HR Needs to know about ADHD; CADDAC
Conference for Allied Health Professionals and Human Resources / Invited
Lecture
Toronto, Ontario, Canada
- 2015 Online Assessment / Invited Lecture
Canadian ADD Resource Alliance, British Columbia, Canada
- 2015 Pay Attention! And We Will Show You How; Canadian ADD Resource
Alliance / Invited Lecture
Vancouver, British Columbia, Canada
- 2017 Functional impairment in ADHD / Invited Lecture
American Professional Society for ADHD and Related Disorders (APSARD),
District of Columbia, United States
- 2020 Ask the Expert / Invited Lecture
American Professional Society for ADHD and Related Disorders (APSARD),
District of Columbia, United States
- 2020 Sleep outcome in clinical trials with 12 and 16 our MPH-MLR / Invited
Lecture

American Professional Society for ADHD and Related Disorders (APSARD),
District of Columbia, United States

- 2020 Symptom Profiles Specific to Trauma, Annual Pediatrics and Neonatology Summit / Invited Lecture
Boston, MA (Virtual)
- 2021 ADHD as a risk factor for severity of COVID-19 infection. / Invited Lecture
American Professional Society for ADHD and Related Disorders (APSARD),
Virtual, United States
- 2021 A Paradigm for Using Function as a Quality Measure / Invited Lecture
American Professional Society for ADHD and Related Disorders
(APSARD), Virtual, United States
- 2021 Management of Sleep Difficulties in ADHD / Invited Lecture
Annual Pediatrics and Neonatology Conference (Virtual)
- 2021 Functional Impairment as a Quality Outcome / Invited Lecture
New York University Visiting Professor, Child Mind Institute
- 2022 The Prevalence and Characteristics of Long COVID Patients with and without
Symptoms of ADHD. / Invited Lecture
American Professional Society for ADHC and Associated Disorders
(APSARD), Arizona

International

- 2001 Advanced Assessment and Treatment of ADD / Symposium
American Psychiatric Association, New Orleans, Louisiana, United States
- 2003 ADHD and the Burden of Illness / Invited Lecture
European Society for Child & Adolescent Psychiatry, 12th International Congress,
France
- 2003 Diagnosis and Treatment of Adult ADHD: Associated Symptoms, Subtypes and
Outcomes / Invited Lecture
American Academy of Child and Adolescent Psychiatry, Miami Beach, Florida,
United States

- 2003 Functional Outcomes of Treated Adults with ADHD / Invited Lecture
American Academy of Child & Adolescent Psychiatry, Beach, Florida, United States
- 2003 Post Hoc Analysis of d-threo-methylphenidate Versus d-l-threo-methylphenidate /
Invited Lecture
American Academy of Child & Adolescent Psychiatry 50th Annual Meeting,
Florida, United States
- 2004 Adult ADHD: Clinical Utility and Validity; / Invited Lecture
American Psychiatric Association 155th Annual Meeting, New York, New York,
United States
- 2004 Evaluating A New Anxiety Screening, Severity and Outcome Measure: “What
If?” / Invited Lecture
American Psychiatric Association 155th Annual Meeting, York, New York,
United States
- 2004 Pilot Study of a New Anxiety Screening Measure for Children / Invited Lecture
American Academy of Child and Adolescent Psychiatry, Washington, District of
Columbia, United States
- 2005 A Review of ADHD; Academy of Child Psychiatry Annual Meeting / Invited
Lecture
Heidelberg, Germany
- 2005 Practice Guidelines for Adults with ADHD / Invited Lecture
National Psychiatric Congress, Ireland
- 2006 Burden of illness in ADHD / Invited Lecture
International Association for Child and Adolescent, Melbourne, Australia
- 2006 Developmental Aspects of ADHD / Invited Lecture
Hague, Groningen, & Utrecht Universities, Netherlands
- 2006 Impact of ADHD Across the Lifespan / Invited Lecture
European Regional Medical Conference, Barcelona, Spain
- 2007 CADDRA: A Model for Korea; Seoul Psychiatry Association / Invited Lecture
Seoul, South Korea

- 2007 Functional Outcomes in ADHD / Invited Lecture
American Academy of Child and Adolescent Psychiatry 54th Annual Meeting,
Massachusetts, United States
- 2007 New Research in ADHD / Invited Lecture
Hong Kong ADHD Support Group, Hong Kong, China
- 2007 New Research in ADHD / Invited Lecture
World Psychiatric Association, Shanghai, China
- 2007 The Role of DSM-IV Rating Scales in Psychiatry / Invited Lecture
American Psychiatric Association Annual Meeting, San Diego, California, United
States
- 2008 An Overview of Working Memory in ADHD / Symposium
American Academy of Child and Adolescent Psychiatry 55th Annual Meeting,
Illinois, United States
- 2008 Effectiveness Outcomes in ADHD, Symposium / Invited Lecture
American Academy of Child and Adolescent Psychiatry 55th Annual Meeting,
Chicago, Illinois, United States
- 2008 Examining Parent and Physician Beliefs on Impact and Comprehensive
Management of ADHD / Invited Lecture
Satellite presentation of the World Federation of Mental Health, American
Academy of Child and Adolescent Psychiatry
- 2008 Impact of Treatment on Patient Outcomes: Cost Utility Analyses / Invited Lecture
Denmark, Finland, Sweden and Norway
- 2008 New Research on Etiological Mechanisms and Clinical Significance of Sleep
Problems in ADHD / Symposium
American Academy of Child and Adolescent Psychiatry 55th Annual Meeting,
Chicago, Illinois, United States
- 2008 Personalizing and Optimizing Individual Outcomes in ADHD / Invited Lecture
Keynote Speaker; Nordic Academy of Child Psychiatry, Norway
- 2008 The Healthy ADHD Child: Eating, Sleeping and Growth / Invited Lecture
Nordic Academy of Child Psychiatry, Norway
- 2008 The World Federation of Mental Health Survey on Perceptions of Social and
Emotional Deficits in ADHD in France, UK, Canada, Mexico, and Germany /

Platform
Global webcast to 750 sites

- 2008 The World Federation of Mental Health Survey on Perceptions of Social and Emotional Deficits in ADHD in France, UK, Canada, Mexico, and Germany / Invited Lecture
International Meeting, Chicago, Illinois, United States
- 2009 Beyond Core Symptoms: Implications of Effectiveness Research for Clinical Practice / Invited Lecture
Keynote speaker; Spanish Academy of Child Psychiatry, Pamplona, Spain
- 2009 Beyond Core Symptoms: Implications of Effectiveness Research for Clinical Practice / Invited Lecture
Scotland Stirling Management Centre, University of Stirling, Stirling, Scotland. Pharmaceutical Company Sponsorship
- 2009 Beyond Core Symptoms: Implications of Effectiveness Research for Clinical Practice / Invited Lecture
Ryegate Children's Centre, Sheffield University, Sheffield, England, United Kingdom. Pharmaceutical Company Sponsorship
- 2009 Beyond Core Symptoms: Implications of Effectiveness Research for Clinical Practice; / Invited Lecture
Bristol University, Badock Hall, Bristol, England. Pharmaceutical Company Sponsorship
- 2009 Beyond Core Symptoms: Implications of Effectiveness Research for Clinical Practice; / Invited Lecture
Royal Manchester Children's Hospital, Manchester, England. Pharmaceutical Company Sponsorship
- 2009 Beyond Core Symptoms: Implications of Effectiveness Research for Clinical Practice; Ashurst Child and Family Centre / Invited Lecture
Ashurst, Southampton, Hampshire, England, United Kingdom. Pharmaceutical Company Sponsorship
- 2009 Functional Outcomes in ADHD / Invited Lecture
2nd International Congress on ADHD, Vienna, Austria
- 2009 Parents and Physicians Beliefs on the Impact and Treatment of ADHD / Invited Lecture

World Federation of Mental Health Study of ADHD; 2nd International Congress on ADHD, Vienna, Austria

- 2009 Setting Up Services for Adult ADHD Under NHS As Per the NICE 2009
Guideline / Invited Lecture
Meeting of the UK Adult ADHD Network, London, England
- 2010 ADHD Symptoms and Quality of Life: How Are They Related? / Invited Lecture
International Association of Child and Adolescent Psychiatry 19th World
Congress, Beijing, China
- 2010 ADHD Through the Life Cycle / Invited Lecture
Keynote Address: Danish Academy of Child and Adolescent Psychiatry, Denmark
- 2010 Activities of Daily Living in Children and Youth with ADHD / Invited Lecture
American Academy of Child and Adolescent Psychiatry, New York, New York,
United States
- 2010 Functional Impairment in ADHD: Optimizing Management by Moving Beyond
Core Symptoms / Invited Lecture
The ADHD Educational Institute, London, England
- 2010 Le Mélatonine et le TDA/H
Premier Congrès International de la Langue Française sur le TDA/H, Bordeaux,
France
- 2010 Les contributions de la recherche pour une meilleure pratique pédopsychiatrique /
Invited Lecture
Key note address, Premier Congrès International de la Langue Française sur le
TDA/H, Bordeaux, France
- 2010 Psychosocial Management Strategies Across the Life Span / Invited Lecture
International Association of Child and Adolescent Psychiatry 19th World
Congress, Beijing, China
- 2010 The Therapy Part of Pharmacotherapy / Invited Lecture
American Academy of Child and Adolescent Psychiatry, New York, New York,
United States
- 2010 Training Workshop for Assessment of ADHD, Teaching Course and Clinical,
Demonstration given to 200 child psychiatrists in China / Workshop
Beijing, China

- 2011 ADHD Through the Life Cycle / Invited Lecture
3rd World Congress ADHD, Berlin, Germany
- 2011 ADHD: Research Review / Invited Lecture
Turku Research Institute, Turku, Finland. Pharmaceutical Company Sponsorship
- 2011 Beyond Core Symptoms of ADHD / Invited Lecture
Gothenburg, Sweden. Pharmaceutical Company Sponsorship
- 2011 CHAOS: The Child Health ADHD Observational Study / Invited Lecture
National Advisory Board for Adult ADHD, NHS, London, England
- 2011 Child Health ADHD Observational Study / Invited Lecture
Keynote plenary address; 3rd World Congress ADHD, Berlin, Germany
- 2011 Functioning, Adaptive Skills and Quality of Life / Invited Lecture
Copenhagen, Denmark. Pharmaceutical Company Sponsorship
- 2011 New Dimensions of Outcome / Invited Lecture
Oslo, Norway. Pharmaceutical Company Sponsorship
- 2011 Public forum on patient education: ADHD / Invited Lecture
3rd World Congress ADHD, Berlin, Germany
- 2011 The Canadian ADHD Network / Symposium
3rd World Congress ADHD, Berlin, Germany
- 2011 Treatment of Adult ADHD / Invited Lecture
3rd World Congress ADHD, Berlin, Germany
- 2011 Working Memory in Real Life (with Torkel Klingberg) / Invited Lecture
Karolinska Institute, Stockholm, Sweden. Pharmaceutical Company Sponsorship
- 2012 Early Intervention for ADHD / Invited Lecture
Plenary Address, World Asian Congress for ADHD, Seoul, Korea.
- 2012 Early Intervention for ADHD Through the Life Cycle / Invited Lecture
Key Note Address: Swiss Academy of Child Psychiatry, Zurich, Switzerland.
Pharmaceutical Company Sponsorship
- 2012 Functional Impairment in ADHD / Invited Lecture
Child Psychiatry Meeting, Madrid, Spain. Pharmaceutical Company Sponsorship

- 2012 Management of ADHD in Canada / Invited Lecture
World Asian Congress for ADHD, Seoul, Korea
- 2013 ADHD and Its Treatments – Clinical Response to Atomoxetine Versus MPH /
Invited Lecture
Gothenburg, Sweden. Pharmaceutical Company Sponsorship
- 2013 ADHD and Its Treatments – Clinical Response to Atomoxetine Versus MPH /
Invited Lecture
Copenhagen, Denmark. Pharmaceutical Company Sponsorship
- 2013 Early Intervention for ADHD / Invited Lecture
Stockholm, Sweden. Pharmaceutical Company Sponsorship
- 2013 Optimizing and Individualizing Treatment for ADHD / Invited Lecture
Bucharest, Romania. Pharmaceutical Company Sponsorship
- 2013 Successful Treatment of ADHD – Expectation and Reality / Invited Lecture
Frankfurt, Germany. Pharmaceutical Company Sponsorship
- 2013 The Economics of ADHD / Invited Lecture
Plenary Address; 4th World Congress on ADHD, Milan, Italy
- 2014 ADHD in DSM 5: Screening, Diagnosis and Prevalence; Neurocongress 2014 /
Invited Lecture
Mexico City, Mexico. Eli Lilly.
- 2014 ADHD in a Family Perspective: The Enigma of Service Delivery in ADHD /
Invited Lecture
Copenhagen, Denmark. Pharmaceutical Company Sponsorship
- 2014 ADHD in a Family Perspective: The Enigma of Service Delivery in ADHD; /
Invited Lecture
Conference – Bridging the Gap, Gothenburg, Sweden. Pharmaceutical Company
Sponsorship
- 2014 Functional Impairment in Adults with ADHD; / Invited Lecture
Neurocongress 2014, Mexico City, Mexico. Eli Lilly.
- 2014 L’Intervention précoce, des effets qui durent pour toujours: Traitement efficace du
TDAH tout au long du cycle de la vie. Plenary address; Conférence TDA/H
Geneva, Switzerland. Pharmaceutical Company Sponsorship

- 2014 L'appréciation clinique et l'évaluation du traitement du TDAH aux adultes: de la recherche à la pratique Clinique; Grands Tours, L'Hôpital Universitaire de l'Université de Genève / Invited Lecture
Geneva, Switzerland. Pharmaceutical Company Sponsorship
- 2015 Quality of Life and Functional Impairment in ADHD; / Invited Lecture
Neurocongress 2015, Ixtapa, Mexico. Eli Lilly
- 2016 Expert Psychopharmacology Consultation / Invited Lecture
Canadian ADD Resource Alliance, Vancouver, British Columbia, Canada
- 2016 The Challenges of High Functioning ADHD / Invited Lecture
United Kingdom Adult ADHD Network, London, England
- 2016 Unwrapping the gifts of ADHD; / Invited Lecture
United Kingdom Adult ADHD Network, London, England
- 2017 Adult ADHD, Plenary Grand Rounds / Invited Lecture
World Federation of ADHD, Vancouver, British Columbia, Canada
- 2017 Functional Impairment in ADHD / Invited Lecture
Plenary Address: Israeli ADHD Network, Tel Aviv, Israel
- 2017 Introduction to ADHD in Adults / Invited Lecture
13th Annual CADDRA ADHD Conference, Quebec City, Quebec, Canada
- 2018 Complex Developmental Trauma and ADHD / Invited Lecture
14th Annual CADDRA ADHD Conference, The Canadian ADHD Resource Alliance, Calgary, Alberta, Canada
- 2018 Perceptions of ADHD – Best Friend or Worst Enemy / Invited Lecture
Round Table Discussion; 5th Eunethydis International Conference, Edinburgh, Scotland
- 2019 The complex interface between ADHD and sleep / Invited Lecture
Hot Topic Session; 7th World Congress on ADHD, Lisbon, Portugal
- 2019 The complex interface between ADHD and sleep / Platform
Webinar, Canadian ADD Resource Alliance, Canada
- 2021 Sleep and ADHD: A 24-hour Disorder, From Research to Action / Platform
Virtual ADHD Summit. Multi-Health Systems

2021 ADHD as a Risk Factor for Infection and Severity of COVID 19 / Invited Lecture
Canadian ADD Resource Alliance, Canada

Report of Clinical Activities and Innovations

Current Licensure and Certification:

1992-2016	Medical License British Columbia
2012-, 2012-, 2012-	Certification Autism Diagnostic Observation Schedule (ADOS) and Autism Diagnostic Interview Training (ADI-R) 2015 Re-certification ADOS 2018 Re-certification ADOS
2016-2019	Arkansas Medical License
2019-	Massachusetts Medical License

Practice Activities:

1988-1992	Affective disorders clinic	Jewish General Hospital, Montreal, Quebec	8 hours / week
1988-1992	Child psychiatry outpatient	Jewish General Hospital, Montreal, Quebec	32 hours / week
1992-1993	Adult Inpatient	St Paul's Hospital, UBC	16 hours / week
1992-1993	Provincial ADHD Program	Children's & Women's Health Centre of British Columbia and Vancouver General Hospital	16 hours / week
1992-1993	UBC Child Mood and Anxiety Disorders Clinic	University of British Columbia, Vancouver	8 hours / week
1992-1999	Neuropsychiatry Clinic	St Paul's Hospital	8 hours / week
1992-2012	Provincial ADHD Program	Children's & Women's Health Centre of British Columbia	36 hours / week

1993-1999	General Teaching Clinic	Children's & Women's Health Centre of British Columbia	8 hours / week
1993-2011	General Child Psychiatry Practice	Children's & Women's Health Centre of British Columbia	8 hours / week
1993-2012	Provincial ADHD Program	British Columbia Children's Hospital	36 hours / week
1998-2003	Adolescent Inpatient Psychiatry	Children's & Women's Health Centre of British Columbia	24 hours / week
2012	Adult and child psychiatry practice	Copeman Healthcare	40 hours / week
2013-2016	Community based clinical practice	Weiss ADHD Care	40 hours / week
2019-2020	Inpatient Child Psychiatrist	Cambridge Health Alliance	27 hours / week
2020-2021	Neurodevelopmental Disorders Clinic	Cambridge Health Alliance	27 hours / week

Clinical Innovations:

Children's and Women's Health Center of British Columbia, University of British Columbia (2004-)

I have more than 40 publications and 75 national and international invited presentations with regards to clinical innovation in the treatment of ADHD in adults. I was instrumental in writing the Canadian guidelines on ADHD in adults, which was the first practice guideline in ADHD to address issues specific to adults. Although it is hard to imagine from our current vantage point, the idea that ADHD could also be a condition in adults was viewed with skepticism at that time and very few psychiatrists were treating ADHD in adults, as noted in the paper "ADHD in Adults: Beyond Controversy" published in Archives of General Psychiatry in 2001. My work on ADHD in adults has covered almost every aspect of assessment and treatment. This includes stimulant and non-stimulant treatment, CBT for ADHD in adults, combination medication and psychological treatment, functional impairment in adult ADHD, sleep disorders, management of comorbid conditions, and oppositional defiant disorder in adults. Each of these innovations have now been widely as a standard of care. In 1996, I published the book "ADHD in Adulthood", together with two of the pioneers of those prospective follow up studies. This book became and remained a classic description of the disorder

and its treatment and is now under revision for a 2nd edition. This work has dramatically changed the lives the 4% of the adult population burdened by this condition.

Effectiveness
outcomes in ADHD
(2007-)

I have been a champion of the idea that clinical trials and clinical treatment needs to move beyond core symptoms to include effectiveness outcomes' such as functional impairment, quality of life, and sleep. I have 14 publications and international presentations exploring effectiveness outcomes, and their relationship to efficacy in management of symptoms. I have been a pioneer in the research methodology for inclusion and interpretation of effectiveness outcomes in clinical trials. This work has led to a shift towards more patient centered care.

Sleep and ADHD
(2007-)

I have been a pioneer in assessment and management of sleep disorders in ADHD in both children and adults. This includes the first study of combination treatment of melatonin and sleep hygiene, incorporation of sleep hygiene into routine practice, use of diaries for clinical assessment of sleep in patients with ADHD, recognition of the functional impairment associated with sleep disorders in ADHD, studies of the impact of stimulants on sleep, and recognition that stimulants may improve sleep in certain patients. My publications and presentations on sleep and ADHD throughout the years have helped raise awareness of ADHD as a '24-hour disorder' manifest as attention and hyperactivity during the day, and difficulty with sleep at night. The role of sleep problems in ADHD is now well-established both as an area of research and clinical care.

Report of Teaching and Education Innovations

Canadian ADD
Resource Alliance
and the Highlighted
Abstract
(2005-)

I was a founding member of a network of professionals working with ADHD called the Canadian Attention Deficit Disorder Resource Alliance (CADDRA). The mission of CADDRA was ongoing education, advocacy and research for professionals working with ADHD. The CADDRA network later inspired the creation of a similar organization in the United States, the American Professional Society for ADHD and Related Disorders. I have participated in the annual conference of both organizations every year and been on both scientific program committees. As part of the education initiative at CADDRA, I developed a tool called the 'Highlighted Abstract', which has remained one of the most popular features of CADDRA membership. I review all new ADHD publications weekly and select publications which capture a novel idea or have significant implications for clinical practice. The abstract is sent out each month by an email push, along with a written commentary on its significance.

Practice Guidelines
for ADHD
(2006-)

The idea of developing practice guidelines came out of a discussion with other Canadian leaders following a national Canadian ADHD meeting in 2004. Together with Dr. Lily Hechtman and Dr. Umesh Jain, I helped write the first practice guidelines published by the Canadian Attention Deficit Disorder Resource Alliance (CADDRA) in 2006. This was the first official national practice guideline for ADHD, and the first to include adults and new measures, two of which I created. These guidelines were instrumental in expanding and improving care for ADHD, both in Canada and globally. The Canadian practice guidelines for ADHD have inspired the creation of other guidelines around the world. I have lectured on the CADDRA guidelines globally and acted as a consultant for creating similar guidelines in other countries. It is hard to underestimate how much the creation of practice guidelines has done to disseminate quality care for ADHD in all ages.

Report of Technological and Other Scientific Innovations

Following the first
laboratory separation
of the d-isomer from
racemic
methylphenidate it
was assumed that
there would be no
clinically significant
differences between
d-MPH and d,l-
MPH. This study
showed some areas
of superiority for the
isomer over the
racemic mixture.
(2004-)

Not patented.
This led to the development of the individual isomer as the drug
dexamethylphenidate (Focalin), which is now one of the first line treatments
for ADHD.

Weiss Functional
Impairment Rating
Scale (WFIRS)
(2005-)

The WFIRS is the intellectual property of Multi-health Systems, a
psychology warehouse that has developed population norms for the measure
and will be launching it in English and French this year.
The Weiss Functional Impairment Rating Scale (WFIRS) has become the
global standard for measurement of functional impairment driven by
emotional and behavior problems in children, adolescents, and adults. The
WFIRS has been translated into 22 languages and validated in samples from
Japan, Thailand, Iran, China, Turkey, Germany, the USA, Canada, Australia,

and Europe in research, clinical and community settings. These studies of the WFIRS have provided us with insight into how to conceptualize functional impairment secondary to emotional issues, and psychometric cut off scores to define functional improvement and functional remission. Since this measure became the intellectual property of Multi-Health Systems, I have been able to collaborate on developing population norms from a sample of 3,130 subjects, which will be the first large, population study of symptom driven functional impairment. The establishment of a global standard to measure outcome has furthered our field to move beyond symptoms to patient centered outcomes and established a paradigm to define functional improvement and remission.

This was the first double blind, placebo controlled clinical trial to show the effectiveness of melatonin with sleep hygiene as an effective treatment for insomnia in ADHD, even in children with initial insomnia secondary to stimulants. This study remains the only study to demonstrate that sleep training combined with melatonin has an additive effect.
(2007)
(2007-)

Not patented.
Not patented.
This study led to global adoption of sleep hygiene and melatonin, alone and in combination, to treat the sleep problems associated with neuropsychiatric disorders in children and adults. This treatment has been so effective that now approximately two thirds of children and adults with ADHD use melatonin, with significant benefit to sleep. Our findings on melatonin for insomnia in ADHD were later replicated in multiple rigorous, randomized clinical trials, although there are still no other studies of combination treatment with sleep hygiene. This was also the first study to develop and evaluate sleep hygiene in children with ADHD, a psychological intervention for sleep problems which is now an active area of development and research. As a result of this work children with neurodevelopmental disorders are now being effectively treated with combination melatonin and sleep hygiene for their sleep problems with a notable improvement in the outcome of both the sleep and the ADHD difficulties. This work received the Elaine Schlosser prize and has been a milestone in the history of treatment of sleep issues in children.

Report of Education of Patients and Service to the Community

No presentations below were sponsored by 3rd parties/outside entities

Activities

2000-2010 Children and Adult Attention Deficit Disorder (CHADD) Canada/ Consultant
Advised on advocacy, policy, education, and medications

Educational Material for Patients and the Lay Community:

Books, monographs, articles and presentations in other media

2012	ADD and Loving It	Participation in the development of a video about ADHD in an adult
2015-2018	ADHD Continuum	Expert advisor on content for web-based education program

Report of Scholarship

ORCID: 0000-0001-8153-8213 Web of Science: Citations 8175, h-index 45, i10-index 91

* Co-author, ** Mentee

Peer-Reviewed Scholarship in print or other media:

Research Investigations

1. Merzon E, **Weiss M**, Krone B, et al. The association between Attention-Deficit/Hyperactivity Disorder and Long COVID Syndrome. *Int J Environ Res Public Health*.
2. Feldman RB, Zelkowitz P, **Weiss M**, Vogel J, Heyman M, Paris J. A comparison of the families of mothers with borderline and nonborderline personality disorders. *Compr Psychiatry*. 1995 Mar-Apr;36(2):157-163. PMID: 7758301
3. **Weiss M**, Zelkowitz P, Feldman RB, Vogel J, Heyman M, Paris J. Psychopathology in offspring of mothers with borderline personality disorder: a pilot study. *Can J Psychiatry*. 1996 Jun;41(5):285-290. PMID: 8793148
4. **Weiss M**, Gaston L, Propst A, Wisebord S, Zicherman V. The role of the alliance in the pharmacologic treatment of depression. *J Clin Psychiatry*. 1997 May;58(5):196-204. PMID: 9184613
5. Johnston C, Fine S, **Weiss M**, Weiss J, Weiss G, Freeman WS. Effects of stimulant medication treatment on mothers' and children's attributions for the behavior of children

with attention deficit hyperactivity disorder. *J Abnorm Child Psychol.* 2000 Aug;28(4):371-382. PMID: 10949961

6. Biederman J, Quinn D, **Weiss M**, Markabi S, Weidenman M, Edson K, Karlsson G, Pohlmann H, Wigal S. Efficacy and safety of Ritalin LA, a new, once daily, extended-release dosage form of methylphenidate, in children with attention deficit hyperactivity disorder. *Paediatr Drugs.* 2003;5(12):833-841. PMID: 14658924
7. **Weiss M**, Tannock R, Kratochvil C, Dunn D, Velez-Borras J, Thomason C, Lambrecht L, Tamura R, Kelsey D, Allen AJ. P.6.072 Placebo-controlled study of once-daily atomoxetine in the school setting. *European Neuropsychopharmacology.* 2003;13(Suppl 4):S456-S7. doi: 10.1016/s0924-977x(03)92370-4. PubMed PMID: WOS:000185412300776.
8. **Weiss M**, Worling D, Wasdell M. A chart review study of the inattentive and combined types of ADHD. *J Atten Disord.* 2003 Sep;7(1):1-9. PMID: 14738177
9. Hechtman L, Abikoff H, Klein RG, Greenfield B, Etcovitch J, Cousins L, Fleiss K, **Weiss M**, Pollack S. Children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment: impact on parental practices. *J Am Acad Child Adolesc Psychiatry.* 2004 Jul;43(7):830-838. PMID: 15213584
10. **Weiss M**, Wasdell M, Patin J. A post hoc analysis of d-threo-methylphenidate hydrochloride (focalin) versus d,l-threo-methylphenidate hydrochloride (ritalin). *J Am Acad Child Adolesc Psychiatry.* 2004 Nov;43(11):1415-1421. PMID: 15502601
11. **Weiss M**, Tannock R, Kratochvil C, Dunn D, Velez-Borras J, Thomason C, Tamura R, Kelsey D, Stevens L, Allen AJ. A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD. *J Am Acad Child Adolesc Psychiatry.* 2005 Jul;44(7):647-655. PMID: 15968233
12. Steele M, **Weiss M**, Swanson J, Wang J, Prinzo RS, Binder CE. A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder. *Can J Clin Pharmacol.* 2006;13(1):e50-e62. PMID: 16456216
13. **Weiss M**, Hechtman L, Adult ADHD Research Group. A randomized double-blind trial of paroxetine and/or dextroamphetamine and problem-focused therapy for attention-deficit/hyperactivity disorder in adults. *J Clin Psychiatry.* 2006 Apr;67(4):611-619. PMID: 16669726
14. **Weiss MD**, Wasdell MB, Bomben MM, Rea KJ, Freeman RD. Sleep hygiene and melatonin treatment for children and adolescents with ADHD and initial insomnia. *J Am*

Acad Child Adolesc Psychiatry. 2006 May;45(5):512-519. PMID: 16670647, [https://doi.org/S0890-8567\(09\)61198-9](https://doi.org/S0890-8567(09)61198-9)

15. Gadow KD, Sprafkin J, Schneider J, Nolan EE, Schwartz J, **Weiss MD**. ODD, ADHD, versus ODD+ADHD in clinic and community adults. *J Atten Disord*. 2007;11(3):374-83. Epub 20070509. doi: 10.1177/1087054706295609. PubMed PMID: 17494826.
16. Iverson GL, Brooks BL, **Weiss MD**, Gualtieri CT, Johnson LG. Clinical usefulness of CNS vital signs for assessing neurocognition in ADHD. *Clinical Neuropsychologist*. Jul 2007;21(4):686-686.
17. Wasdell MB, Jan JE, Bomben MM, Freeman RD, Rietveld WJ, Tai J, Hamilton D, **Weiss MD**. A Randomized Placebo-Controlled Trial of Melatonin Treatment of Circadian Rhythm Sleep Disorders in Children with Neurodevelopmental Disabilities. *Journal of Pineal Research*. 2007;43(4):253-8.
18. Jain U, Hechtman L, **Weiss M**, Ahmed TS, Reiz JL, Donnelly GA, Harsanyi Z, Darke AC. Efficacy of a novel biphasic controlled-release methylphenidate formula in adults with attention-deficit/hyperactivity disorder: results of a double-blind, placebo-controlled crossover study. *J Clin Psychiatry*. 2007 Feb;68(2):268-277. PMID: 17335326
19. Kratochvil CJ, Michelson D, Newcorn JH, **Weiss MD**, Busner J, Moore RJ, Ruff DD, Ramsey J, Dickson R, Turgay A, Saylor KE, Luber S, Vaughan B, Allen AJ, Atomoxetine High-Dose Study G. High-dose atomoxetine treatment of ADHD in youths with limited response to standard doses. *Journal of the American Academy of Child and Adolescent Psychiatry*. 2007;46(9):1128-37. Epub 2007/08/23. doi: 10.1097/chi.0b013e318074eeb3. PubMed PMID: 17712236.
20. Sprafkin J, Gadow KD, **Weiss MD**, Schneider J, Nolan EE. Psychiatric comorbidity in ADHD symptom subtypes in clinic and community adults. *J Atten Disord*. 2007 Sep;11(2):114-124. PMID: 17494828
21. **Weiss M**, Hechtman L, Turgay A, Jain U, Quinn D, Ahmed TS, Yates T, Reiz JL, Donnelly GA, Harsanyi Z, Darke AC. Once-daily multilayer-release methylphenidate in a double-blind, crossover comparison to immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder. *J Child Adolesc Psychopharmacol*. 2007 Oct;17(5):675-688. PMID: 17979587
22. Carr R, Wasdell MB, Hamilton D, **Weiss MD**, Freeman RD, Tai J, Rietveld WJ, Jan JE. Long-term effectiveness outcome of melatonin therapy in children with treatment-

resistant circadian rhythm sleep disorders. *J Pineal Res.* 2007;43(4):351-9. Epub 2007/10/04. doi: 10.1111/j.1600-079X.2007.00485.x. PubMed PMID: 17910603.

23. Wilens TE, Adler LA, **Weiss MD**, Michelson D, Ramsey JL, Moore RJ, Renard D, Brady KT, Trzepacz PT, Schuh LM, Ahrbecker LM, Levine LR, Atomoxetine ASUDSG. Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders. *Drug Alcohol Depend.* 2008;96(1-2):145-54. Epub 20080409. doi: 10.1016/j.drugalcdep.2008.02.009. PubMed PMID: 18403134.
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't. *Drug Alcohol Depend.* Jul 1, 2008;96(1-2):145-54. doi:10.1016/j.drugalcdep.2008.02.009
24. Cheung A, Kusumakar V, Kutcher S, Dubo E, Garland J, **Weiss M**, Kiss A, Levitt A. Maintenance study for adolescent depression. *J Child Adolesc Psychopharmacol.* 2008 Aug;18(4):389-394. PMID: 18759650, <https://doi.org/10.1089/cap.2008.0001>
25. Greenfield B, Henry M, **Weiss M**, Tse SM, Guile JM, Dougherty G, Zhang X, Fombonne E, Lis E, Lapalme-Remis S, Harnden B. Previously suicidal adolescents: predictors of six-month outcome. *J Can Acad Child Adolesc Psychiatry.* 2008 Nov;17(4):197-201. PMID: 19018322, PMCID: PMC2583916
26. Newcorn JH, Sutton VK, **Weiss MD**, Sumner CR. Clinical responses to atomoxetine in attention-deficit/hyperactivity disorder: the Integrated Data Exploratory Analysis (IDEA) study. Research Support, Non-U.S. Gov't. *Journal of the American Academy of Child and Adolescent Psychiatry.* May 2009;48(5):511-518. doi:10.1097/CHI.0b013e31819c55b2
27. **Weiss M**, Panagiotopoulos C, Giles L, Gibbins C, Kuzeljevic B, Davidson J, Harrison R. A naturalistic study of predictors and risks of atypical antipsychotic use in an attention-deficit/hyperactivity disorder clinic. *J Child Adolesc Psychopharmacol.* 2009 Oct;19(5):575-582. PMID: 19877982, <https://doi.org/10.1089/cap.2009.0050>
28. Manos M, Frazier TW, Landgraf JM, **Weiss M**, Hodgkins P. HRQL and medication satisfaction in children with ADHD treated with the methylphenidate transdermal system. *Curr Med Res Opin.* 2009 Dec;25(12):3001-3010. PMID: 19849639, <https://doi.org/10.1185/03007990903388797>
29. Frazier TW, **Weiss M**, Hodgkins P, Manos MJ, Landgraf JM, Gibbins C. Time course and predictors of health-related quality of life improvement and medication satisfaction in children diagnosed with attention-deficit/hyperactivity disorder treated with the methylphenidate transdermal system. Multicenter Study

Randomized Controlled Trial. *J Child Adolesc Psychopharmacol*. Oct 2010;20(5):355-64. doi:10.1089/cap.2009.0092

30. Gibbins C, **Weiss MD**, Goodman DW, Hodgkins PS, Landgraf JM, Faraone SV. ADHD-hyperactive/impulsive subtype in adults. *Ment Illn*. 2010 Jan 25;2(1):e9. PMID: 25478092, PMCID: PMC4253348, <https://doi.org/10.4081/mi.2010.e9>
31. **Weiss MD**, Gibbins C, Goodman DW, Hodgkins PS, Landgraf JM, Faraone SV. Moderators and mediators of symptoms and quality of life outcomes in an open-label study of adults treated for attention-deficit/hyperactivity disorder. *Comparative Study. J Clin Psychiatry*. Apr 2010;71(4):381-90. doi:10.4088/JCP.08m04709pur
32. Kiddie JY, **Weiss MD**, Kitts DD, Levy-Milne R, Wasdell MB. Nutritional status of children with attention deficit hyperactivity disorder: a pilot study. *Int J Pediatr*. 2010;2010:767318. Epub 20100628. doi: 10.1155/2010/767318. PubMed PMID: 20652039; PubMed Central PMCID: PMC2905905.
33. Frazier TW, **Weiss M**, Hodgkins P, Manos MJ, Landgraf JM, Gibbins C. Time course and predictors of health-related quality of life improvement and medication satisfaction in children diagnosed with attention-deficit/hyperactivity disorder treated with the methylphenidate transdermal system. *J Child Adolesc Psychopharmacol*. 2010 Oct;20(5):355-364. PMID: 20973706, <https://doi.org/10.1089/cap.2009.0092>
34. **Weiss MD**, Wasdell M, Gadow KD, Greenfield B, Hechtman L, Gibbins C. Clinical correlates of oppositional defiant disorder and attention-deficit/hyperactivity disorder in adults. *Postgraduate medicine*. 2011;123(2):177-84. Epub 2011/04/09. doi: 10.3810/pgm.2011.03.2276. PubMed PMID: 21474906.
35. Dickson RA, Maki E, Gibbins C, Gutkin SW, Turgay A, **Weiss MD**. Time courses of improvement and symptom remission in children treated with atomoxetine for attention-deficit/hyperactivity disorder: analysis of Canadian open-label studies. *Child Adolesc Psychiatry Ment Health*. 2011 May 11;5:14. PMID: 21569378, PMCID: PMC3120776, <https://doi.org/10.1186/1753-2000-5-14>
36. Rogers M, Hwang H, Toplak M, **Weiss M**, Tannock R. Inattention, working memory, and academic achievement in adolescents referred for attention deficit/hyperactivity disorder (ADHD). *Child Neuropsychol*. 2011;17(5):444-458. PMID: 21390917, <https://doi.org/10.1080/09297049.2010.544648>
37. **Weiss M**, Murray C, Wasdell M, Greenfield B, Giles L, Hechtman L. A randomized controlled trial of CBT therapy for adults with ADHD with and without medication.

BMC Psychiatry. 2012 Apr 5;12:30. PMID: 22480189, PMCID: PMC3414742, <https://doi.org/10.1186/1471-244X-12-30>

38. Gibbins C, Toplak ME, Flora DB, **Weiss MD**, Tannock R. Evidence for a general factor model of ADHD in adults. *J Atten Disord*. 2012 Nov;16(8):635-644. PMID: 22076604, <https://doi.org/10.1177/1087054711416310>
39. Johnston C, **Weiss MD**, Murray C, Miller NV. The effects of instructions on mothers' ratings of attention-deficit/hyperactivity disorder symptoms in referred children. *Journal of abnormal child psychology*. 2014;42(3):479-88. doi:10.1007/s10802-013-9789-x
40. Borgelt EL, Buchman DZ, **Weiss M**, Illes J. In search of "anything that would help": parent perspectives on emerging neurotechnologies. *J Atten Disord*. 2014 Jul;18(5):395-401. PMID: 22617864, <https://doi.org/10.1177/1087054712445781>
41. Tarakçioğlu MC, Memik NÇ, Olgun NN, Aydemir Ö, **Weiss MD**. Turkish validity and reliability study of the Weiss Functional Impairment Rating Scale-Parent Report. *Atten Defic Hyperact Disord*. 2015 Jun;7(2):129-139. PMID: 25428590, <https://doi.org/10.1007/s12402-014-0158-6>
42. Stein MA, Sikirica V, **Weiss MD**, Robertson B, Lyne A, Newcorn JH. Does Guanfacine Extended Release Impact Functional Impairment in Children with Attention-Deficit/Hyperactivity Disorder? Results from a Randomized Controlled Trial. *CNS Drugs*. 2015 Nov;29(11):953-962. PMID: 26547425, PMCID: PMC4653245, <https://doi.org/10.1007/s40263-015-0291-6>
43. Cheung A, Levitt A, Cheng M, Santor D, Kutcher S, Dubo E, Jane Garland E, **Weiss M**, Kiss A. A Pilot Study of Citalopram Treatment in Preventing Relapse of Depressive Episode after Acute Treatment. *J Can Acad Child Adolesc Psychiatry*. 2016;25(1):11-16. PMID: 27047552, PMCID: PMC4791101
44. Owens J, **Weiss M**, Nordbrock E, Mattingly G, Wigal S, Greenhill LL, Chang WW, Childress A, Kupper RJ, Adjei A. Effect of Aptensio XR (Methylphenidate HCl Extended-Release) Capsules on Sleep in Children with Attention-Deficit/Hyperactivity Disorder. *J Child Adolesc Psychopharmacol*. 2016 Dec;26(10):873-881. PMID: 27754700, PMCID: PMC5178023
45. Takeda T, Tsuji Y, Kanazawa J, Sakai T, **Weiss MD**. Psychometric properties of the Japanese version of the Weiss Functional Impairment Rating Scale: Self-Report. *Atten Defic Hyperact Disord*. Sep 2017;9(3):169-177. doi:10.1007/s12402-016-0213-6
46. Hodgkins P, Lloyd A, Erder MH, Setyawan J, **Weiss MD**, Sasané R, Nafees B. Estimating minimal important differences for several scales assessing function and

quality of life in patients with attention-deficit/hyperactivity disorder. *CNS Spectr*. 2017 Feb;22(1):31-40. PMID: 27535815, <https://doi.org/10.1017/S1092852916000353>

47. Williamson D, Johnston C, Noyes A, Stewart K, **Weiss MD**. Attention-Deficit/Hyperactivity Disorder Symptoms in Mothers and Fathers: Family Level Interactions in Relation to Parenting. *J Abnorm Child Psychol*. 2017 Apr;45(3):485-500. PMID: 27909931, <https://doi.org/10.1007/s10802-016-0235-8>
48. Thompson T, Lloyd A, Joseph A, **Weiss M**. The Weiss Functional Impairment Rating Scale-Parent Form for assessing ADHD: evaluating diagnostic accuracy and determining optimal thresholds using ROC analysis. *Qual Life Res*. 2017 Jul;26(7):1879-1885. PMID: 28220338, PMID: PMC5486894, <https://doi.org/10.1007/s11136-017-1514-8>
49. Johnston C, Williamson D, Noyes A, Stewart K, **Weiss MD**. Parent and Child ADHD Symptoms in Relation to Parental Attitudes and Parenting: Testing the Similarity-Fit Hypothesis. *J Clin Child Adolesc Psychol*. 2018;47(sup1):S127-S136. doi:10.1080/15374416.2016.1169538
50. Kiani B, Hadianfard H, **Weiss MD**. Descriptive and psychometric properties of the Persian version of the Weiss functional impairment rating scale: parent report form in Iranian children. *Health Qual Life Outcomes*. Dec 7 2018;16(1):225. doi:10.1186/s12955-018-1053-1
51. **Weiss M**, Childress A, Mattingly G, Nordbrock E, Kupper RJ, Adjei AL. Relationship Between Symptomatic and Functional Improvement and Remission in a Treatment Response to Stimulant Trial. *J Child Adolesc Psychopharmacol*. 2018 Oct;28(8):521-529. PMID: 30036076, PMID: PMC6201781, <https://doi.org/10.1089/cap.2017.0166>
52. Addicott MA, Schechter JC, Sapyta JJ, Selig JP, Kollins SH, **Weiss MD**. Methylphenidate increases willingness to perform effort in adults with ADHD. *Pharmacol Biochem Behav*. Aug 2019;183:14-21. doi:10.1016/j.pbb.2019.06.008
53. Hadianfard H, Kiani B, **Weiss MD**. Psychometric Properties of the Persian Version of the Weiss Functional Impairment Rating Scale-Self-Report Form in Iranian Adolescents. *J Atten Disord*. Nov 1 2019;23(13):1600-1609. doi:10.1177/1087054717738084
54. **Weiss M**, Childress A, Mattingly G, Nordbrock E, Kupper RJ, Adjei AL. Relationship Between Symptomatic and Functional Improvement and Remission in a Treatment Response to Stimulant Trial. *J Child Adolesc Psychopharmacol*. Oct 2018;28(8):521-529. doi:10.1089/cap.2017.0166
55. **Weiss M**, Childress A, Nordbrock E, Adjei AL, Kupper RJ, Mattingly G. Characteristics of ADHD Symptom Response/Remission in a Clinical Trial of Methylphenidate

Extended Release. *J Clin Med*. 2019 Apr 5;8(4). PMID: 30959790, PMCID: PMC6517933, <https://doi.org/E461>

56. Micoulaud-Franchi JA, Weibel S, **Weiss M**, Gachet M, Guichard K, Bioulac S, Philip P, Jausse I, Dauvilliers Y, Lopez R. Validation of the French Version of the Weiss Functional Impairment Rating Scale-Self-Report in a Large Cohort of Adult Patients With ADHD. *J Atten Disord*. 2019 Aug;23(10):1148-1159. PMID: 30191748, <https://doi.org/10.1177/1087054718797434>
57. Craig SG, **Weiss MD**, Hudec KL, Gibbins C. The Functional Impact of Sleep Disorders in Children With ADHD. *J Atten Disord*. Feb 2020;24(4):499-508. doi:10.1177/1087054716685840
58. Tarakcioglu M, Caliskan Y, Kadak M, Aliyev N, Aksoy U, Tufan A, Gundogdu O, Memik N, **Weiss M**. Is Functional Improvement Always Correlated with Symptomatic Improvement in Children With Attention-Deficit/Hyperactivity Disorder Managed with Oros Methylphenidate? A Prospective Open-Label Naturalistic Follow-Up Study. *Psychiatry and Clinical Psychopharmacology*. 2020;30(2):128-35. doi: 10.5455/pcp.20200526011248.
59. Addicott MA, Pearson JM, Schechter JC, Sapyta JJ, **Weiss MD**, Kollins SH. Attention-deficit/hyperactivity disorder and the explore/exploit trade-off. *Neuropsychopharmacology*. 2021 Feb;46(3):614-621. PMID: 33040092, PMCID: PMC8027173, <https://doi.org/10.1038/s41386-020-00881-8>
60. Hadianfard H, Kiani B, **Weiss MD**. Study of Functional Impairment in Students of Elementary and Secondary Public Schools in Iran. *J Can Acad Child Adolesc Psychiatry*. 2021 May;30(2):68-81. PMID: 33953759, PMCID: PMC8056958
61. **Weiss MD**, Surman C, Khullar A, He E, Cataldo M, Donnelly G. Effect of a Multi-Layer, Extended-Release Methylphenidate Formulation (PRC-063) on Sleep in Adults with ADHD: A Randomized, Double-Blind, Forced-Dose, Placebo-Controlled Trial Followed by a 6-month Open-Label Extension. *CNS Drugs*. 2021 Jun;35(6):667-679. PMID: 34057707, PMCID: PMC8219576, <https://doi.org/10.1007/s40263-021-00814-z>
62. **Weiss MD**, Surman C, Khullar A, He E, Cataldo M, Donnelly G. Effect of a Multi-Layer, Extended-Release Methylphenidate Formulation (PRC-063) on Sleep in Adults with ADHD: A Randomized, Double-Blind, Forced-Dose, Placebo-Controlled Trial Followed by a 6-month Open-Label Extension. *CNS Drugs*. Jun 2021;35(6):667-679. doi:10.1007/s40263-021-00814-z
63. **Weiss MD**, Childress AC, Donnelly GAE. Efficacy and Safety of PRC-063, Extended-Release Multilayer Methylphenidate in Adults with ADHD Including 6-Month Open-

Label Extension. *J Atten Disord.* 2021 Aug;25(10):1417-1428. PMID: 31916473, PMID: PMC8273537, <https://doi.org/10.1177/1087054719896853>

64. **Weiss MD**, Childress AC, Donnelly GAE. Efficacy and Safety of PRC-063, Extended-Release Multilayer Methylphenidate in Adults with ADHD Including 6-Month Open-Label Extension. *J Atten Disord.* Aug 2021;25(10):1417-1428. doi:10.1177/1087054719896853
65. Greenfield G, Okoli O, Quezada-Yamamoto H, et al. Characteristics of frequently attending children in hospital emergency departments: a systematic review. *BMJ open.* Oct 18 2021;11(10):e051409. doi:10.1136/bmjopen-2021-051409
66. Greenfield B, Jolicoeur-Martineau A, Brown M, Kandiyoti A, Henry M, Sasson T, Ahmadi S, Vivani T, Harnden B, de Castro F, Tran B, Boodaghians L, **Weiss M**, Atsaidis Z, Wazana A. Frequent follow-up of suicidal youth assessed in the emergency room: Long-term trajectory and predictors of suicidality. *Prev Med.* 2021 Nov;152(Pt 1):106737. PMID: 34538378, [https://doi.org/S0091-7435\(21\)00306-6](https://doi.org/S0091-7435(21)00306-6)
67. **Weiss MD**, Cutler AJ, Kollins SH, Donnelly GAE. Efficacy and Safety of a Long-Acting Multilayer-Release Methylphenidate Formulation (PRC-063) in the Treatment of Adolescent Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind Clinical Trial with a 6-Month Open-Label Extension. *J Child Adolesc Psychopharmacol.* 2021 Nov;31(9):610-622. PMID: 34637343, <https://doi.org/10.1089/cap.2021.0034>
68. **Weiss MD**, Surman C, Khullar A, et al. Effect of a Multilayer, Extended-Release Methylphenidate Formulation (PRC-063) on Sleep in Adolescents with Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Fixed-Dose, Placebo-Controlled Trial Followed by a 6-Month Open-Label Follow-Up. *J Child Adolesc Psychopharmacol.* Nov 2021;31(9):623-630. doi:10.1089/cap.2021.0087
69. Merzon E, **Weiss MD**, Cortese S, Rotem A, Schneider T, Craig SG, Vinker S, Golan Cohen A, Green I, Ashkenazi S, Weizman A, Manor I. The Association between ADHD and the Severity of COVID-19 Infection. *J Atten Disord.* 2022 Feb;26(4):491-501. PMID: 33797281, <https://doi.org/10.1177/10870547211003659>
70. Robinson LA, Gaugh L, Yapo S, Al-Sumairi R, Lorenzo A, **Weiss M**. Defragmenting the path to diagnosis for underserved youth with Autism Spectrum Disorder in a community-based health system. *Healthc (Amst).* 2022 Mar;10(1):100597. PMID: 35144168, [https://doi.org/S2213-0764\(21\)00080-4](https://doi.org/S2213-0764(21)00080-4)

Non-peer reviewed scholarship in print or other media:

Reviews, chapters, monographs and editorials

1. **Weiss MD**, Rostain A, Carson N, Gander S. Perspectives on the Pediatric Syndemic: Losses and Opportunities. *World Social Psychiatry*. In Press.
2. **Weiss MD**, Stein MA. Measurement-Informed Care in Attention-Deficit/Hyperactivity Disorder (ADHD). *Child Adolesc Psychiatr Clin N Am*. 2022/05/11/2022;doi:https://doi.org/10.1016/j.chc.2022.03.010
3. **Weiss M**, Schachter D. A role for catecholamines in the pathogenesis of neuroleptic malignant syndrome. *Can J Psychiatry*. 1986;31(1):66-69.
4. **Weiss M**, Bond M, Bouffard R. The development of defenses in childhood. *Can J Psychiatry*. 1989;34(6):581-8.
5. Weiss, M. Treating the sibling subsystem: an adjunct of divorce therapy. *Am J Orthopsychiatry*. 1989;59(2):226-37. Epub 1989/04/01. doi: 10.1111/j.1939-0025.1989.tb01654.x. PubMed PMID: 2712156.
6. **Weiss M**. Psychoeducational intervention with the family, school and child with Attention Deficit Hyperactivity Disorder. *Child Adolesc Psychiatr Clin North Am*. 1992;1:467-81.
7. **Weiss M**, Baerg E, Wisebord S, Temple J. The influence of gonadal hormones on periodicity of obsessive-compulsive disorder. *Can J Psychiatry*. 1995 May;40(4):205-207. PMID: 7621390
8. **Weiss M**, Hechtman L, Weiss G. ADHD in parents. *J Am Acad Child Adolesc Psychiatry*. 2000 Aug;39(8):1059-1061. PMID: 10939236
9. **Weiss M**, Jain U, Garland J. Clinical suggestions for management of stimulant treatment in adolescents. *Can J Psychiatry*. 2000 Oct;45(8):717-723. PMID: 11086554
10. Murray C, **Weiss M**. Assessment of adult ADHD: current guidelines and issues. *Anuario De Psicologia*. 2001;32:23-33.
11. Gadow KD, **Weiss M**. Attention-deficit/hyperactivity disorder in adults: beyond controversy. *Arch Gen Psychiatry*. 2001 Aug;58(8):784-785. PMID: 11483145
12. **Weiss MD**, Weiss, G. Attention Deficit Hyperactivity Disorder. In: Lewis M, editor. *Child and Adolescent Psychiatry: A Comprehensive Textbook*. Philadelphia: Lippincott Williams & Wilkins; 2002.
13. **Weiss M**, Murray C, Weiss G. Adults with attention-deficit/hyperactivity disorder: current concepts. *J Psychiatr Pract*. 2002 Mar;8(2):99-9111. PMID: 15985863

14. **Weiss M**, Murray C. Assessment and management of attention-deficit hyperactivity disorder in adults. *CMAJ*. 2003 Mar 18;168(6):715-722. PMID: 12642429, PMCID: PMC154919
15. **Weiss MD**, Weiss JR. A guide to the treatment of adults with ADHD. *J Clin Psychiatry*. 2004;65 Suppl 3:27-37. Epub 2004/03/30. PubMed PMID: 15046533.
16. Adler LA, **Weiss MD**. Clinical Implication of New Research in Attention-Deficit/Hyperactivity Disorder in Adults. *J Clin Psychiatry*. 2004;5(1):1-8.
17. **Weiss MD**, Gadow K, Wasdell MB. Effectiveness outcomes in attention-deficit/hyperactivity disorder. *J Clin Psychiatry*. 2006;67 Suppl 8:38-45. Epub 2006/09/12. PubMed PMID: 16961429.
18. Biederman J, Arnsten AF, Faraone SV, Doyle AE, Spencer TJ, Wilens TE, **Weiss MD**, Safren SA, Culpepper L. New developments in the treatment of ADHD. *J Clin Psychiatry*. 2006;67(1):148-59. Epub 2006/01/24. doi: 10.4088/jcp.v67n0121. PubMed PMID: 16426101.
19. **Weiss M**, Wasdell M, Faulkner L, Rea K, Freeman R, Weiss G, Jokhani V. Atomoxetine in clinical practice. *Future Neurology*. 2006;1(3):249-58.
20. **Weiss MD**, Gadow K, Wasdell MB. Effectiveness outcomes in attention-deficit/hyperactivity disorder. Research Support, Non-U.S. Gov't Review. *J Clin Psychiatry*. 2006;67 Suppl 8:38-45.
21. Jan JE, Wasdell MB, Reiter RJ, **Weiss MD**, Johnson KP, Ivanenko A, Freeman RD. Melatonin therapy of pediatric sleep disorders: Recent advances, why it works, who are the candidates and how to treat. *Current Pediatric Reviews*. 2007;3:214-24.
22. Jan JE, Wasdell MB, **Weiss MD**, Freeman RD. What is the correct dose of melatonin in sleep therapy? *Biological Rhythm Research*. 2007;38(2):85-6. doi: 10.1080/09291010701275669.
23. Nutt DJ, Fone K, Asherson P, Bramble D, Hill P, Matthews K, Morris KA, Santosh P, Sonuga-Barke E, Taylor E, **Weiss M**, Young S, British Association for P. Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology. *J Psychopharmacol*. 2007;21(1):10-41. Epub 20061108. doi: 10.1177/0269881106073219. PubMed PMID: 17092962.
24. Stein M, **Weiss MD**, Leventhal B. ADHD by night: sleep problems and ADHD medications. *Child and Adolescent Psychopharmacology News*. 2007;12(6):1-5.

25. **Weiss MD**, Hunter J, Gibbins C. Management of ADHD in adults. *Perspectives in Psychiatry*. 2007;4(4):17-20.
26. Newcorn JH, **Weiss M**, Stein MA. The complexity of ADHD: diagnosis and treatment of the adult patient with comorbidities. *CNS Spectr*. 2007 Aug;12(8 Suppl 12):1-14; quiz 15. PMID: 17667893
27. Gibbins C, **Weiss M**. Clinical recommendations in current practice guidelines for diagnosis and treatment of ADHD in adults. *Curr Psychiatry Rep*. 2007 Oct;9(5):420-426. PMID: 17915083
28. **Weiss M**, Safren SA, Solanto MV, Hechtman L, Rostain AL, Ramsay JR, Murray C. Research forum on psychological treatment of adults with ADHD. *J Atten Disord*. 2008 May;11(6):642-651. PMID: 18417729, <https://doi.org/10.1177/1087054708315063>
29. Jan JE, Owens JA, **Weiss MD**, Johnson KP, Wasdell MB, Freeman RD, Ipsiroglu OS. Sleep hygiene for children with neurodevelopmental disabilities. *Pediatrics*. 2008;122(6):1343-50. Epub 2008/12/03. doi: 10.1542/peds.2007-3308. PubMed PMID: 19047255.
30. Warren AE, Hamilton RM, Belanger SA, et al. Cardiac risk assessment before the use of stimulant medications in children and youth: A joint position statement by the Canadian Paediatric Society, the Canadian Cardiovascular Society, and the Canadian Academy of Child and Adolescent Psychiatry. *Canadian Journal of Cardiology*. Nov 2009;25(11):625-630.
31. **Weiss MD**, Yeung C, Rea K, Poitras S, Goldstein S. The soft underbelly of research in the psychosocial treatment of ADHD. *J Atten Disord*. 2009;12(5):391-3. Epub 2009/02/17. doi: 10.1177/1087054708329780. PubMed PMID: 19218541.
32. **Weiss M**. [During sleep the brain becomes a building site]. *MMW Fortschr Med*. 2009 Sep 10;151(37):18. PMID: 19827420
33. Bélanger SA, Warren AE, Hamilton RM, Gray C, Gow RM, Sanatani S, Côté JM, Frcpc JL, Leblanc J, Martin S, Miles B, Mitchell C, Gorman DA, **Weiss M**, Schachar R. Cardiac risk assessment before the use of stimulant medications in children and youth. *Paediatr Child Health*. 2009 Nov;14(9):579-592. PMID: 21037835, PMCID: PMC2806076
34. Hamilton R, Gray C, Bélanger SA, Warren AE, Gow RM, Sanatani S, Côté JM, Lougheed J, LeBlanc J, Martin S, Miles B, Mitchell C, Gorman DA, **Weiss M**, Schachar R. Cardiac risk assessment before the use of stimulant medications in children and youth: A joint position statement by the Canadian Paediatric Society, the Canadian

Cardiovascular Society and the Canadian Academy of Child and Adolescent Psychiatry. *J Can Acad Child Adolesc Psychiatry*. 2009 Nov;18(4):349-355. PMID: 19881947, PMCID: PMC2765391

35. Epstein JN, **Weiss MD**. Assessing treatment outcomes in attention-deficit/hyperactivity disorder: a narrative review. *The primary care companion to CNS disorders*. 2012;14(6). Epub 2012/11/29. doi: 10.4088/PCC.11r01336. PubMed PMID: 23585986; PubMed Central PMCID: PMC3622525.
36. **Weiss MD**, Salpekar J. Sleep problems in the child with attention-deficit hyperactivity disorder: defining aetiology and appropriate treatments. *CNS Drugs*. 2010;24(10):811-28. Epub 2010/09/16. doi: 10.2165/11538990-000000000-00000. PubMed PMID: 20839894.
37. Owens J, Brown T, Corkum P, et al. Updated Clinical Practice Guidelines on AD/HD: The Importance of Sleep. *Pediatrics*. 2011;On line(On line):2011-2064.
38. **Weiss MD**, Baer S, Allan BA, Saran K, Schibuk H. The screens culture: impact on ADHD. *Atten Defic Hyperact Disord*. 2011;3(4):327-34. Epub 2011/09/24. doi: 10.1007/s12402-011-0065-z. PubMed PMID: 21948003; PubMed Central PMCID: PMC3220824.
39. **Weiss MD**, Childress A, M. P, L. H. Review of long-acting stimulant and nonstimulant ADHD pharmacotherapy in Canada. *J Can Acad Child Adolesc Psychiatry*. 2011;19(4).
40. **Weiss MD**, Elbe, D., Virani, A.. Drugs for ADHD. In: Bezchlibnyk-Butler K, Virani A, editors. *Clinical Handbook for Drugs in Children and Adolescents*. 19th ed. Cambridge, MA, USA: Hogrefe; 2011. p. 232-303.
41. **Weiss MD**, Gibbins, C., Hunter, J. ADHD and Anxiety Disorders in Adults. In: Buitelaar J, Kan, C.C., Asherson, P., editor. *ADHD in Adults: Characterization, Diagnosis, and Treatment*. Cambridge, UK: Cambridge University Press; 2011. p. 130-8.
42. Hinshaw SP, Scheffler RM, Fulton BD, Aase H, Banaschewski T, Cheng W, Mattos P, Holte A, Levy F, Sadeh A, Sergeant JA, Taylor E, **Weiss MD**. International variation in treatment procedures for ADHD: social context and recent trends. *Psychiatr Serv*. 2011;62(5):459-64. Epub 2011/05/03. doi: 10.1176/ps.62.5.pss6205_0459. PubMed PMID: 21532069.
43. **Weiss MD**. Functional Impairment in ADHD. In: Adler LA, Spencer TJ, Wilens TE, editors. *Attention-Deficit Hyperactivity Disorder in Adults and Children*. Cambridge, United Kingdom: Cambridge University Press; 2012. p. 42-52.

44. Bond DJ, Hadjipavlou G, Lam RW, McIntyre RS, Beaulieu S, Schaffer A, **Weiss M**, Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid attention-deficit/hyperactivity disorder. *Ann Clin Psychiatry*. 2012 Feb;24(1):23-37. PMID: 22303520
45. Seixas M, **Weiss M**, Müller U. Systematic review of national and international guidelines on attention-deficit hyperactivity disorder. *J Psychopharmacol*. 2012 Jun;26(6):753-765. PMID: 21948938, <https://doi.org/10.1177/0269881111412095>
46. Stein MA, **Weiss M**, Hlavaty L. ADHD treatments, sleep, and sleep problems: complex associations. *Neurotherapeutics*. 2012 Jul;9(3):509-517. PMID: 22718078, PMCID: PMC3441938, <https://doi.org/10.1007/s13311-012-0130-0>
47. Epstein JN, **Weiss MD**. Assessing treatment outcomes in attention-deficit/hyperactivity disorder: a narrative review. *Prim Care Companion CNS Disord*. 2012;14(6). PMID: 23585986, PMCID: PMC3622525, <https://doi.org/10.4088/PCC.11r01336>
48. Owens J, Gruber R, Brown T, Corkum P, Cortese S, O'Brien L, Stein M, **Weiss M**. Future research directions in sleep and ADHD: report of a consensus working group. *J Atten Disord*. 2013;17(7):550-64. Epub 20120913. doi: 10.1177/1087054712457992. PubMed PMID: 22982880.
49. **Weiss MD**. Review: Limited evidence that risperidone reduces aggression and conduct problems in the short term in children and adolescents with disruptive behaviour disorders. *Evid Based Ment Health*. 2013;16(3):69. Epub 20130416. doi: 10.1136/eb-2012-101086. PubMed PMID: 23592637.
50. Cortese S, Brown TE, Corkum P, Gruber R, O'Brien LM, Stein M, **Weiss M**, Owens J. Assessment and management of sleep problems in youths with attention-deficit/hyperactivity disorder. *J Am Acad Child Adolesc Psychiatry*. 2013 Aug;52(8):784-796. PMID: 23880489, <https://doi.org/10.1016/j.jaac.2013.06.001>
51. Owens J, Gruber R, Brown T, Corkum P, Cortese S, O'Brien L, Stein M, **Weiss M**. Future research directions in sleep and ADHD: report of a consensus working group. *J Atten Disord*. 2013 Oct;17(7):550-564. PMID: 22982880, <https://doi.org/10.1177/1087054712457992>
52. Stein M, **Weiss M**. Sleep Problems and Interventions in Preschoolers with ADHD. In: Ghuman Ga, editor. *ADHD in Preschool Children: Assessment and Treatment*. 198 Madison Avenue, New York, NY 10016: Oxford University Press; 2014. p. 210 - 20.

53. Craig SG, Davies G, Schibuk L, **Weiss MD**, Hechtman L. Long-Term Effects of Stimulant Treatment for ADHD: What Can We Tell Our Patients? *Curr Dev Disord Rep*. 2015;2(1):1-9. doi: 10.1007/s40474-015-0039-5.
54. **Weiss MD**, Craig SG, Davies G, Schibuk L, Stein M. New Research on the Complex Interaction of Sleep and ADHD. *Current Sleep Medicine Reports*. 2015;1(2):114-21. doi: 10.1007/s40675-015-0018-8.
55. **Weiss MD**, McBride NM, Craig S, Jensen P. Conceptual review of measuring functional impairment: findings from the Weiss Functional Impairment Rating Scale. *Evid Based Ment Health*. 2018;21(4):155-64. Epub 20181012. doi: 10.1136/ebmental-2018-300025. PubMed PMID: 30314990; PubMed Central PMCID: PMC6241626.
56. **Weiss MD**, Surman CBH, Elbe D. Stimulant 'rapid metabolizers': wrong label, real phenomena. *Atten Defic Hyperact Disord*. 2018;10(2):113-8. Epub 20171104. doi: 10.1007/s12402-017-0242-9. PubMed PMID: 29103196.
57. **Weiss MD**, Ivanenko A, McBride NM. Assessing Sleep Problems in ADHD. In: Hiscock H, Sciberras E, eds. *Sleep and ADHD, An Evidence Based Guide to Assessment and Treatment*. London, England: Elsevier; 2019. p. 195 - 213.; 2018.
58. Russell D, **Weiss M**, Stein MA. A Maximum Dose for Methylphenidate-How Much Is Too Much?. *JAMA Pediatr*. 2019 Jul 1;173(7):621-622. PMID: 31135823, <https://doi.org/10.1001/jamapediatrics.2019.0911>
59. Craig SG, Bondi BC, O'Donnell KA, Pepler DJ, **Weiss MD**. ADHD and Exposure to Maltreatment in Children and Youth: a Systematic Review of the Past 10 Years. *Curr Psychiatry Rep*. 2020;22(12):79. Epub 20201108. doi: 10.1007/s11920-020-01193-w. PubMed PMID: 33161561.
60. Childress AC, Beltran N, Supnet C, **Weiss MD**. Reviewing the role of emerging therapies in the ADHD armamentarium. *Expert Opin Emerg Drugs*. 2021 Mar;26(1):1-16. PMID: 33143485, <https://doi.org/10.1080/14728214.2020.1846718>
61. Hechtman L, **Weiss MD**, Hwang P. Attention deficit/hyperactivity disorder in children. In: Boland R, Verduin M, P R, editors. *Comprehensive textbook of psychiatry*. New York: Wolters Kluwer 2021.

Books/textbooks for the medical or scientific community

1. Weiss, M., Trokenberg Hechtman, L., Weiss, G. *ADHD in Adulthood: A guide to current theory, diagnosis and treatment*. Baltimore and London, Johns Hopkins University Press, 1999.

2. Gadow, K., Sprafkin, J., Weiss, M.D., *Adult Self-Report Inventory 4 Manual*. Stony Brook, NY, USA: Checkmate Plus, 2004.
3. Jain U, Hechtman, L., Quinn, D., Turgay, A., Yaremko, J., Mutch, C., Sacks, D., Weiss, M., Maziade, M. *Canadian ADHD Practice Guidelines*. 1st ed. Toronto, Ontario, Canada: Canadian Attention Deficit Hyperactivity Disorder Resource Alliance 2006.
4. **Weiss MD**, Vincent, A., Jain, U., Hechtman, L., Smith, D., Gignac, M., Laurence, J., Proulx, S. *The CADDRA Practice Guidelines*. 3rd ed. Toronto, Ontario, Canada: Canadian Attention Deficit Resource Alliance; 2011.

Case reports

1. Garland EJ, **Weiss M**. Case study: obsessive difficult temperament and its response to serotonergic medication. *J Am Acad Child Adolesc Psychiatry*. 1996 Jul;35(7):916-920. PMID: 8768352
2. Myronuk LD, **Weiss M**, Cotter L. Combined treatment with moclobemide and methylphenidate for comorbid major depression and adult attention-deficit/hyperactivity disorder. *J Clin Psychopharmacol*. 1996 Dec;16(6):468-469. PMID: 8959481
3. Gonzalez-Heydrich J, **Weiss M**, Connolly M, Wambera K, Jan JE, Plioplys S, Dunn DW, Kratochvil CJ. Pharmacological management of a youth with ADHD and a seizure disorder. *J Am Acad Child Adolesc Psychiatry*. 2006 Dec;45(12):1527-1532. PMID: 17135999
4. **Weiss M**. Case report: complex ADHD presentation in adolescence. *CNS Spectr*. 2009 Nov;14(11 Suppl 9):7-10. PMID: 20173699
5. **Weiss M**, Allan B, Greenaway M. Treatment of catatonia with electroconvulsive therapy in adolescents. *J Child Adolesc Psychopharmacol*. 2012 Feb;22(1):96-9100. PMID: 22339614, <https://doi.org/10.1089/cap.2010.0052>
6. **Weiss MD**, Schibuk L, Gokarakonda SB, Henderson R, Esmaeilpour D. Catatonia with Psychosis in an 8-Year-Old Child: A Case Report and a Literature Review. *Case Rep Psychiatry*. 2022;2022:4124733. doi:10.1155/2022/4124733 In Press.

Letters to the Editor

1. Garland EJ, **Weiss M**. Subgroups of adolescent depression. *J Am Acad Child Adolesc Psychiatry*. 1995 Jul;34(7):831-833. PMID: 7649950

2. **Weiss M**, Garland J. More on PANDAS -letter-. J Am Acad Child Adolesc Psychiatry. 1997 Sep;36(9):1163-1165. PMID: 9291714
3. **Weiss M**, Murray C. ADHD and driving safety / The authors respond. Can Med Assoc J. 2003;169(1):16-. PubMed PMID: WOS000184077300016.
4. Owens J, Brown T, Corkum P, et al. Letter to the Editor Regarding the Updated Clinical Practice Guidelines on AD/HD: The Importance of Sleep. Pediatrics. 2011;On line(Online):2011-2064.

Professional educational materials or reports, in print or other media:

1. **Weiss M**. Changes in the approach to pharmacotherapy for ADHD. Child and Adolescent Psychopharmacology News. 1996;1(1):5-9. NOT IN FILE.
2. **Weiss M**, Walkup JT. Clinically Applied Pharmacokinetics of the SSRIs and SNRIs. Child and Adolescent Psychopharmacology News. 1997;2(3):1-9.
3. **Weiss M**, Faulkner L. Titration of stimulant medication. Child and Adolescent Psychopharmacology News. 2000;5(Supplement).
4. **Weiss MD**, Jain U. Clinical Perspectives on the Assessment of ADHD in Adolescence. The ADHD Report. 2000;8(6):4-10.
5. **Weiss MD**. Commentary on Melatonin for Sleep Onset Insomnia. The Brown University Psychopharmacology Update. 2007;9(3):4-.

Thesis:

1. Margaret Danielle Schibuk, "The Search for Vaccinia". PhD dissertation, Harvard University; 1986.

Abstracts, Poster Presentations and Exhibits Presented at Professional Meetings:

1. Ling DS, **Weiss M**, Murray C, Diamond A. Patients with ADHD are being overmedicated for optimal cognitive performance. . International Brain Research Organization; Daegu, Korea2019.
2. **Weiss MD**, Labs AI. Expectancy and Treatment Experience with a Novel Digital Treatment for Pediatric Attention-Deficit Hyperactivity Disorder (ADHD). Children with Attention Deficit Disorder (CHADD); November 7, 2019; Philadelphia, PA: CHADD; 2019.

3. **Weiss MD**, Ramkhalawansingh R, Solomon J. Exploring Gender-Related Differences in the Behavioural Manifestation of ADHD. American Professional Society of ADHD and Related Disorders; Washington, D.C.2020.

Narrative Report

Introduction

I am a child and adult psychiatrist who specializes in the care of neurodevelopmental disorders such as ADHD and Autism Spectrum Disorder. After completing my PhD in the History and Philosophy of Science at Harvard and my MD, I joined the faculty of psychiatry at McGill. In 1992, I moved to British Columbia where I directed the Provincial ADHD Program for 15 years. When the Royal College of Canada made child psychiatry a separate specialty, I took the fellowship exam (2015) and officially became a child and an adult psychiatrist. In 2016 I accepted a three-year appointment at University of Arkansas Medical Sciences and Arkansas Children's Hospital as Director of Child Psychiatry. In 2019, I accepted a position as the Director of Research for Child Psychiatry at Cambridge Health Alliance.

Area of Excellence: Clinical Expertise

As Director of the Provincial ADHD Program in British Columbia, I helped grow an interdisciplinary clinical and research center of excellence, which hosted visiting scholars from China, the Philippines, the United States, Mexico, and Japan. This team provided consultation on complex ADHD cases for the province, seeing up to 600 new cases/year. I also worked in the mood and anxiety disorders clinic, the neuropsychiatry clinic, and the adolescent inpatient unit. I was trained and certified every two years in the Autism Diagnostic Observation Scale and the Autism Developmental Interview – Revised and provided assessment and treatment for children and adults with autism. As Director of Child Psychiatry at University of Arkansas Medical Sciences, I gained experience in assessment and treatment of complex trauma, and evidence-based psychotherapies such as Trauma Focused Cognitive Behavior Therapy and Parent Child Interaction Therapy. I have worked in the Neurodevelopmental Clinic at Cambridge Health Alliance seeing children and youth with ADHD and Autism Spectrum Disorder, and in the child and adolescent inpatient units as the Interim Medical Director.

Area of Excellence: Innovation

I have developed the Weiss Functional Impairment Rating Scale (WFIRS). The WFIRS has become a global standard for measurement of functional impairment. It has been translated into 22 languages, validated in 7 different research and clinical settings, and normed on 3,130 subjects. These are the first population norms to be obtained on functional impairment secondary to behavior and emotional problems. This work has contributed to innovation in understanding the importance of patient centered effectiveness outcomes, and evaluation of functional improvement and remission. In 2007, I published a randomized, placebo-controlled trial of melatonin and sleep hygiene in management of initial insomnia in patients with ADHD on stimulant medication, a study which received the Elaine Schlosser award from the American Academy of Child and Adolescent Psychiatry. We demonstrated that sleep hygiene was effective, that melatonin was highly effective as compared to placebo, and that combination treatment was superior to sleep hygiene or melatonin alone. I recently published several studies looking at sleep outcome in patients receiving stimulants. These studies have demonstrated that more patients have improvement in sleep while on stimulants than experience insomnia. I am recognized as a key opinion

leader in ADHD. I wrote one of the early textbooks on ADHD in adults, which is now under revision. I have co-authored multiple editions of the Canadian practice guidelines for ADHD and am now working on the latest revision. I have co-authored the chapter on ADHD previously and then again in the most recent edition of the *Comprehensive Textbook of Child Psychiatry*.

Teaching:

I have taught the behavior course for first year medical students at McGill. I have supervised and taught medical students, residents, child fellows, and research trainees. For the last three years I coordinated the psychopharmacology course for the first-year child psychiatry fellows. This year I authored a new curriculum for this course, which provides an integrated perspective on assessment, measurement informed care, and psychological and medication treatment of the most common child mental health disorders. My evaluations uniformly score > 4.5/5, with comments such as, “She brings a rare combination of research/evidence-based thinking and decades of clinical expertise.” and “Dr. Weiss has been more than a teacher this past year, she’s been a steady rock during a difficult time for all of us”.

Supporting Activity: Investigation

I have been the principal- or co-investigator of 17 peer reviewed grants, many from national funding agencies such as Canadian Institute for Health Research or the National Institute of Mental Health. I have 70 peer reviewed publications reporting on results of original research investigations. I have contributed to the sparse literature on combination treatment with original investigations looking at the outcome of CBT with and without medication in management of adults with ADHD and Problem Focused Therapy alone or in combination with either an antidepressant, a stimulant, or both for treatment of adults with ADHD and internalizing symptoms. My study comparing isomeric and racemic methylphenidate contributed to the development of dexamethylphenidate, now a first line stimulant in the treatment of ADHD. I conducted one of the early studies of nutrition in ADHD, demonstrating that many children with ADHD have low ferritin and zinc. I published an inpatient investigation identifying which specific symptoms were most likely to be associated with complex trauma. I have recently collaborated with Israeli investigators in three studies demonstrating that ADHD is associated with increased likelihood of infection with COVID, severity of COVID and long COVID syndrome. I have been a principal investigator or site investigator in 15 clinical trials of new medication treatments for ADHD. I was the principal investigator for the international trial looking at school outcomes for atomoxetine and one of the few clinical trials looking at outcome of stimulant treatment in adolescents. I am currently funded on the Methods Core of a NIMH grant, the Early Screening and Treatment of High-Risk Youth (eSToRY). The objective of E-SToRY is to better identify and understand disparities in mental health for youth at risk. The objective of the methods core is to seamlessly integrate large administrative datasets and integrate input from clinical and services researchers and community stakeholders. I am the principal investigator of the NIMH R34 study: Prevention and Early Identification for High-Risk Youth in School Based Clinics (1P50MH126283-01). This research project provides a novel approach to screening, early assessment, and preventive interventions for high-risk youth in race, ethnicity, and language diverse communities. I have submitted a grant application to the Patient Centered Outcome Research Institute (PCORI) looking at comparative effectiveness of medications for management of behavior problems in intellectual disability, and how medication management is moderated by social determinants of health.

Summary:

I have written 134 peer reviewed papers, with a web of science H-Index of 32, and 3,456 citations, as well as book chapters, books, and manuals. I developed a rating scale that has become a gold standard

for evaluation of functional impairment secondary to emotional and behavior problems in both children and adults. I am an internationally recognized key opinion leader in the areas of ADHD, ADHD and sleep, and ADHD in adults. I have lectured as an invited speaker in 22 countries, in both French and in English. I have held leadership positions in two countries and taught and mentored junior faculty both clinically and in research. I have been a full professor at both the University of British Columbia and the University of Arkansas Medical Sciences. My best work has always been at the interface between clinical care and research, and this perspective has inspired my teaching, and served as the foundation of my leadership. It is a privilege to work with the remarkable community of clinicians, teachers, and researchers I have found in the Harvard community, and to look to the future in crafting the tools we will need to meet the challenges we face with the current mental health pandemic in youth.